_pmid,_doi,_publicationTitle,_year,_toolName,_toolType,_usageType,usageId,publicationId,resourceId
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,spheroid culture system,advanced_cellular_models,Experimental Usage,265a25f9-0d17-5538-a707-13fdbdc85b74,10088f76-3416-594d-a08b-efff5ad7f29f,4f95c143-9441-51a0-ab5b-e8f5b7cdac0f
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,TAME chips,advanced_cellular_models,Experimental Usage,cc1f70db-2f9f-5557-aab4-f37af852cf7b,27a13990-aba5-5e01-8feb-c90d3acf8e8a,14313702-6f1d-53aa-9e69-b743cca3438d
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,3D rBM overlay model,advanced_cellular_models,Experimental Usage,0652498a-43d2-5724-a0a3-327f8af94e8f,1753ccb3-b4f9-5369-9ae3-20e48a267351,a2e8a2a7-8ca9-55f3-a360-83c729440728
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cNF organoids,advanced_cellular_models,Development,09319e0f-5268-5479-823b-603ba4ab9796,c85145d2-03f6-5ed2-971c-370356cf4a08,fa394cc7-9f63-5714-af1b-4240eaa62112
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,129T2/SvEmsJ::C57Bl/6NTac Nf1+/- and Nf1+/+,animal_models,Experimental Usage,07348120-bd1a-5215-8860-96911519f612,677306bb-4529-56a9-9491-9481a23b9c60,9c816cb8-6187-5283-95bb-c35bca36e57a
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,C57BL6/J Nf1+/−;Trp53+/−,animal_models,Experimental Usage,7c46eddf-a1ee-5eda-b857-06ae05950835,4c500643-3c43-5c39-a015-aae7aacba58e,92d2e667-6bf8-5dcc-9f16-9a6f2c08394a
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 c.5425 C > T ; Arg1809Cys,animal_models,Experimental Usage,e3d42c70-413e-5603-9212-ebd59a3553a9,686ba2dd-21f7-5c0f-9c35-4a10134fe88f,59983fe4-e778-519b-b91e-eb1331dfc1ad
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,R681X Nf1,animal_models,Experimental Usage,5795eea1-c6bd-50c5-87ab-65476c6564d7,686ba2dd-21f7-5c0f-9c35-4a10134fe88f,4027ec9e-7379-583a-99a1-69db7e0df51e
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 flox/flox ; Hoxb7-Cre,animal_models,Experimental Usage,baf08612-a6a8-58b4-af25-7ca843967fc6,686ba2dd-21f7-5c0f-9c35-4a10134fe88f,0e503f20-aacd-5634-a510-d313b55dc81f
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 f/neo ; hGFAP-Cre,animal_models,Experimental Usage,d226f6ff-18b5-58cb-923c-e0857891a167,686ba2dd-21f7-5c0f-9c35-4a10134fe88f,32bf181d-ea22-556e-b56b-cc54d16a4ab7
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IF,animal_models,Experimental Usage,6e25bae2-5a5a-5630-bffc-ac8fed88ec82,abb89502-7575-51d1-9884-ddca97a2d316,9ef4e72f-27a8-5a62-898e-da5059be3278
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-PS,animal_models,Experimental Usage,f172eede-ba76-5868-9a24-af16894d7830,abb89502-7575-51d1-9884-ddca97a2d316,db1873f0-9852-563e-b595-a46452d0b540
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IFPS,animal_models,Experimental Usage,6bfa5b4f-c39c-5f39-9c22-68bd2b62719d,abb89502-7575-51d1-9884-ddca97a2d316,badc395b-6692-5782-b3e4-00d8fd731040
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1(ob) (-/-),animal_models,Experimental Usage,65bdcb27-8dea-5744-b95f-b09b6bc687c0,6b5c6af2-fd8f-50bb-be17-0d6f652bf2e4,b7cbe81f-e9db-5fab-9564-521b0c878ecf
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,2.3-kb α1(I) collagen-cre Nf1 flox/flox,animal_models,Experimental Usage,b4493abe-45f7-51b0-ab51-76391ebbaec4,6b5c6af2-fd8f-50bb-be17-0d6f652bf2e4,56436cb7-cfed-5976-9200-23f810a66b9c
PMID:36890585 | PMID:40684195 | PMID:19191334 | PMID:21439418 | PMID:34935315 | PMID:25772366 | PMID:29847659 | PMID:29787563 | PMID:28525381 | PMID:25535838 | PMID:20200958,10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1002/glia.20845 | 10.1016/j.bone.2011.03.760 | 10.1117/1.JBO.26.12.125001 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1371/journal.pone.0190001 | 10.18632/oncotarget.17589 | 10.7554/eLife.05151 | 10.1002/jbmr.42,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox,animal_models,Experimental Usage,31fc933a-9926-557e-ac82-54c27e3967ef,aafab7fa-57c6-5772-a716-a6f8e840d144,2433f01f-8ef3-514a-978a-93a449dcc8b4
PMID:33078583 | PMID:21681782 | PMID:21551250 | PMID:21726432 | PMID:32839340 | PMID:18242513,10.1002/jcsm.12632 | 10.1002/ajh.22035 | 10.1158/0008-5472.CAN-10-4577 | 10.1186/1741-7015-9-82 | 10.1073/pnas.2008391117 | 10.1016/j.ccr.2008.01.003,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1. | Brain-wide structural and functional disruption in mice with oligodendrocyte-specific | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1 flox,animal_models,Experimental Usage,c9863d36-bfb1-55e0-b652-ebb5108b60ba,2a4fed50-5e45-5d25-933d-55983b5ef506,ba5ab76b-b23e-5258-9d61-886f4ab09510
PMID:32781282 | PMID:21199799 | PMID:8582272 | PMID:21949590 | PMID:40590220 | PMID:36890585 | PMID:40684195 | PMID:23071067 | PMID:26190969 | PMID:21439418 | PMID:25772366 | PMID:29847659 | PMID:18242513 | PMID:28525381 | PMID:16835260 | PMID:18632543,10.1016/j.trsl.2020.08.001 | 10.1158/0008-5472.CAN-10-2732 | 10.1242/dev.121.11.3583 | 10.2478/v10134-010-0025-8 | 10.1172/JCI188932 | 10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1158/0008-5472.CAN-12-1728 | 10.3389/fncel.2015.00234 | 10.1016/j.bone.2011.03.760 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1016/j.ccr.2008.01.003 | 10.18632/oncotarget.17589 | 10.1093/hmg/ddl165 | 10.1001/jama.300.3.287,"Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. | Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. | Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. | In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.",,Nf1+/-,animal_models,Experimental Usage,3873cc85-c204-5736-a91b-e233733bbcab,f0ff9980-306a-5559-b983-797c60215a28,9c821f99-a92d-5fcc-b512-8607480ae168
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,y w Mer4,animal_models,Experimental Usage,8ed72099-27d6-5470-944c-c02fdc9be99b,6ccd0d5d-b7c5-52b3-a737-0616dfc1de15,ce320a62-9c23-56c1-a31e-86a5bd53bbb8
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,4/FM7; T80-Gal4 y w Mer4,animal_models,Experimental Usage,2ec230b9-13e3-5a07-8e32-2b48e7e15db6,6ccd0d5d-b7c5-52b3-a737-0616dfc1de15,b1c5c572-3b5c-52a6-a910-33321c4f1828
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,PLP CreERT2; Nf1 f/−; ROSA-LacZ,animal_models,Experimental Usage,d5c0aa09-acec-5c4b-afc6-03209e4f9d86,871381ec-7d04-5cd1-8c2a-9ba7d229cf0d,64c128f0-d5ad-571d-a6d2-4a466d982210
PMID:34935315 | PMID:24465906 | PMID:21726432,10.1117/1.JBO.26.12.125001 | 10.1371/journal.pone.0086115 | 10.1186/1741-7015-9-82,"Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.",,Nf1Prx1-/-,animal_models,Experimental Usage,9723547a-af2c-5523-869e-8c9aafaec251,33713fe4-cdb9-5114-9d7c-ce6b33196915,d6ef2a65-bc56-578e-a426-a8e42388839b
PMID:21963652 | PMID:19191334 | PMID:23225063 | PMID:25772366,10.1016/j.expneurol.2011.09.005 | 10.1002/glia.20845 | 10.1002/ana.23793 | 10.1016/j.celrep.2015.02.041,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Nf1+/− GFAP CKO,animal_models,Experimental Usage,4697e983-734b-5944-aa5e-c378d3f039bc,157002e6-1d6a-5d47-b499-9e54000418a0,edade01d-5b28-5d39-b592-a2355cac456a
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Nf1(flox/-);Col2.3Cre(+),animal_models,Development,7c785260-2168-53a0-8f72-a56037c387c9,237083d8-a4df-5306-8928-7e703f490388,359e011a-d18d-5ec9-9e8b-1b264e17c46c
PMID:38502231 | PMID:34010628,10.1172/JCI176748 | 10.1016/j.stem.2021.04.029,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,cisNP,animal_models,Experimental Usage,1cfa8425-6bc0-5b8e-a070-5239ef51d0a3,41b94877-07c4-5734-92ec-f2ec19389730,866607df-5a44-5eae-9b1e-8d6411ecb745
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,animal_models,Experimental Usage,01997269-b7ea-53ed-9c35-15893a1f07f2,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,38365203-9446-583d-a77b-e07fb3a87d2b
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,P{ KK101909 }VIE‐260B,animal_models,Experimental Usage,d07749fb-3cb5-54d5-b806-e77ec1fd26ed,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,06ff776b-fea8-54f5-b727-9abca4ce187d
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,Nf1Dsk9/+,animal_models,Experimental Usage,a120d146-8501-5370-b5df-9a786c87943c,caa2a2ba-b781-5b6b-99cf-28995148fc14,40599842-43f7-5565-b886-5dc649e0d30d
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,P0SchΔ39-121,animal_models,Experimental Usage,999d079d-9f9a-5dea-a676-2624d1c77424,c4212dfb-c3a0-5330-9964-28aa270669bc,b25925a3-6f19-5e5b-be0c-42a0782b9c79
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"Trp53, Nf1, Suz12 triple mutant",animal_models,Experimental Usage,8b57badd-124d-5cb0-93dc-a47262bb3759,4c38f0c0-ab7c-5f15-a15c-3501dc6b7a9d,5eb80e47-0cdb-5b04-ba4d-98e4c6d6a91c
PMID:33442015 | PMID:31527226 | PMID:33658640 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1158/1535-7163.MCT-19-0123 | 10.1038/s41416-021-01270-8 | 10.1158/1078-0432.CCR-23-2548,"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.",,Nf1flox/flox;PostnCre,animal_models,Experimental Usage,f23c0cec-9519-5dd9-ba28-4937de120ce5,f257f505-0b66-507d-9214-2e0e2216f226,b28a9b9d-7cad-566a-af24-fabd2d1c9444
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,NF1 fl/fl Tp53 fl/fl Eed fl/fl;Dhh-Cre,animal_models,Experimental Usage,2ec16849-b804-5f23-99b9-c4f2efaf005b,dedce255-85c0-5393-a506-95313062ed5a,cba9e7f2-5307-57c3-a000-be83339d7221
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 R1947/+,animal_models,Development,d5468e1e-7a00-5b22-9b0e-6da76eded166,d2f07474-f43f-50f7-abc1-ecf76627be65,9f90706d-5b59-553d-9743-1eb6dbc61c5d
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Nf1fl/fl,animal_models,Experimental Usage,704d28cd-950d-5001-a308-2f727fda4e48,9a3e4289-b548-5076-830c-a47d7c0f1c37,c910dd12-e034-5ad1-bad3-44c6b4b96de6
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,OPG Nf1fl/mut (Nf1+/−),animal_models,Experimental Usage,c59864a0-bb27-52aa-931f-abc6caecccba,9a3e4289-b548-5076-830c-a47d7c0f1c37,03d2ffe3-ea87-5e39-894c-adc7cb5da85d
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 hGFAP CKO,animal_models,Experimental Usage,25e91219-a79c-50b4-aa97-8cc42be7f511,9c33f2c2-8d6b-5387-a09b-d1eaf1d44dd0,8948e47d-3bbf-5cb8-ba55-74c15a4f3e96
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 NcreER CKO,animal_models,Experimental Usage,a83c56a6-73b5-5cbf-93c2-6863902a60ff,9c33f2c2-8d6b-5387-a09b-d1eaf1d44dd0,a4552f3c-0475-5da9-81fa-9e9b89c1b6a0
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Nf1 fcr,animal_models,Experimental Usage,25e96956-61b7-548b-bbdb-1d961300bceb,a5fe76ac-01db-575a-9b9f-a6cb84e753d8,cb2faad8-e4ab-54ab-9286-f4f4544b40f5
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,NPcis,animal_models,Experimental Usage,89bf6783-64b6-515b-9621-9636e30e5a4c,10088f76-3416-594d-a08b-efff5ad7f29f,f8ad311d-5503-5185-8331-bb3622c60dda
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",animal_models,Experimental Usage,95dbd751-9253-51b9-a8c5-355dcb5ff80d,d58c9faf-ef15-514d-8927-2bf7edb94535,66988b6a-7f49-5b92-b5cf-58db189fc582
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,Postn-Cre; Nf2flox/flox,animal_models,Experimental Usage,2dbbe7c5-5f3d-5ff0-8ff9-6c857c99cee1,7243854d-d552-5224-9365-c80163e526ae,912ab836-55cc-5769-bab0-ad1201b989f4
PMID:41444363 | PMID:24817309 | PMID:17924978 | PMID:38945076,10.1038/s41598-025-32031-9 | 10.1371/journal.pone.0097320 | 10.1111/j.1750-3639.2007.00105.x | 10.1016/j.redox.2024.103249,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. | Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Nf2flox/flox,animal_models,Experimental Usage,069d1cd2-d8c5-5bba-9ec9-66d132214e17,def708c3-3301-5833-beb4-ebdaa21e3411,95087676-d95f-5986-8a19-a7491d31d4f7
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,"Dhh::Cre, Nf1fl/fl, Pten",animal_models,Experimental Usage,0bde040d-f123-5735-a459-1e3aaf2c8bce,c079a8f5-6f86-5f1e-8b61-d414dade9904,f5cbd630-c2a5-5c55-8dd6-7db2cda555e9
PMID:21216928 | PMID:26883872 | PMID:20551058,10.1158/1535-7163.MCT-10-0654 | 10.1016/j.jprot.2016.02.004 | 10.1158/0008-5472.CAN-09-3769,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. | 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Nf1 flox/flox; GFAP-Cre,animal_models,Experimental Usage,aa9f335a-f6ea-5487-af8c-485e16caa5b2,fb519c11-4475-503c-a214-4f70f7d71196,4a5e5e77-eb10-5cbf-bc35-521ffdda67f4
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,DhhCre;Nf1fl/fl,animal_models,Experimental Usage,b8a1aac9-001e-55d8-9f5b-6f6f9df7a5da,6a6cc4a3-4377-5ef4-b773-91aa74274ce7,58b5ecc6-5290-5dc9-aa53-358a7a70fad1
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,Nf1Col1,animal_models,Experimental Usage,a809914e-827f-52ef-a5d7-87dd0c5e48f5,7a307ee7-dcbe-5a2c-b5d6-eda885997737,bd9636e4-d1b2-5181-a19b-29cd24f4f64d
PMID:28256556 | PMID:26904939,10.1038/srep43315 | 10.1016/j.celrep.2016.01.074,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Nf1fl/fl;DhhCre,animal_models,Experimental Usage,fba7e54a-ffe4-512a-a65d-5ca7b791de26,3faa91a7-20eb-51c4-ba33-1184ee72a33d,d835ef05-a6e7-5269-adec-43e288108932
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Stat3(fl/fl);Nf1(fl/fl);DhhCre,animal_models,Experimental Usage,c9f6d736-eaf6-5846-9b96-d28efa1588f9,2b8fbee9-0206-5b19-9ff9-247ef34d29a4,5ad65882-986b-5a72-86a2-69e3b6d8a5c6
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;Nes-TK,animal_models,Experimental Usage,735845bd-9ab7-5b78-bd72-d37ec4826a8b,ba823898-11fb-563f-a020-049e503d0c86,019086d3-2877-507f-946f-4a350906b3c5
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;CGD,animal_models,Experimental Usage,6adf5054-983a-5c7d-99d8-e505596269c7,ba823898-11fb-563f-a020-049e503d0c86,22f30826-2dc3-5a19-a9b6-22427fdbcd0b
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1/p53-/-,animal_models,Experimental Usage,c93b485c-45b6-5c60-8244-22840643d0a9,d4789358-b1c7-59fc-b751-686ac6dcea4f,3f1d08b5-7f28-5444-b71f-adb4546b3066
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,9a−/9a− Nf1,animal_models,Experimental Usage,ef7d2d2c-a816-526f-b737-23eb9ee1e4a1,e3bd187b-66ad-5162-918e-b129edfa65bb,ac709e73-9f67-5ce8-9835-bd64d2f50993
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Nf2 flox2/flox2 ;p16 Ink4a*/*,animal_models,Experimental Usage,29db96ef-92b0-5e5a-b5c5-6f74902ea825,e532a697-bb23-5363-bd4c-58daf43d1095,a0443d94-cf21-5ff9-bea5-10c21c67b6e7
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,H7;Nf1mut,animal_models,Experimental Usage,af31d962-cdc4-5a0d-923d-e662a4e70cd8,f84f7c73-c19d-515b-93ad-9c99aae0cc9a,f03b3b12-dc42-540a-8105-3147d425fb1f
PMID:24375753 | PMID:20551058 | PMID:28525381,10.1002/ana.24093 | 10.1158/0008-5472.CAN-09-3769 | 10.18632/oncotarget.17589,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut;GFAP-Cre,animal_models,Experimental Usage,de61011a-2956-573f-b4d0-b078f6431aa4,d5c80af7-6449-5664-b157-9e41d6034f4a,3a865aff-eb92-5ed3-a87b-6ccc9db254fe
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,DhhCre,animal_models,Experimental Usage,56c69026-dea5-5cf8-a422-7c9adb60a7e8,ac913aa3-1735-549f-bc14-f889b6fc4af2,b8f5e9c2-6b81-5c2b-bc67-44eaa3d0cc72
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Nf1flox/flox;Arf flox/flox;PostnCre+,animal_models,Experimental Usage,75257fc2-c0fc-55a8-b782-81b0f64e3d09,ac913aa3-1735-549f-bc14-f889b6fc4af2,6303a527-7a77-5149-a18b-479f76908051
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/wt,animal_models,Experimental Usage,9927f347-58f5-5aa7-869d-975ba0192533,5c99cec1-6803-516d-b5a4-81969d0d6528,5ffaafc6-5cfc-5ef4-b3fd-e89ad69b4560
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut,animal_models,Experimental Usage,a8610f0b-5482-5580-af9a-0b72a58ee9dc,5c99cec1-6803-516d-b5a4-81969d0d6528,1bd5aaf0-4cc3-592c-897a-9e801384b9b6
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Olig2-Cre,animal_models,Experimental Usage,16ac34e7-7ccf-573d-be93-eb99289b7532,5c99cec1-6803-516d-b5a4-81969d0d6528,c1738be3-7190-5eed-8f1e-44c26b7840cf
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Olig2-Cre,animal_models,Experimental Usage,552d1ccb-e913-54ee-81a6-06e72b392fda,5c99cec1-6803-516d-b5a4-81969d0d6528,72b463a4-9450-5933-9ee9-144f93c2e642
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Prom1-CreER,animal_models,Experimental Usage,d54eb6a8-34ca-5acd-beb8-7cdb2f26016c,5c99cec1-6803-516d-b5a4-81969d0d6528,9831ac31-0d36-5fac-9acf-a05868bb41cf
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Prom1-CreER,animal_models,Experimental Usage,4ea2fd9e-e5ad-5176-940c-4943b1375f01,5c99cec1-6803-516d-b5a4-81969d0d6528,c4168bda-acf2-50c3-b7a4-adf9290dab55
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl,animal_models,Experimental Usage,30c31e05-3a1e-5a9a-9798-69a213f20363,865f5011-5b7e-5810-85d5-63c582ea12bf,680350a0-4047-53d0-a656-b2023afec10d
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl YAP fl/fl,animal_models,Experimental Usage,f4ef5c8c-e8e9-5760-8b89-6239cccbf57a,865f5011-5b7e-5810-85d5-63c582ea12bf,2db4c5f8-aa40-5224-8496-b01342a63231
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl TAZ fl/fl,animal_models,Experimental Usage,028f111d-53b3-5e69-ae5f-eda1524267cc,865f5011-5b7e-5810-85d5-63c582ea12bf,707cc2cc-7915-5ee8-8ff5-909b0be068fd
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,P0-CRE,animal_models,Experimental Usage,38a97521-ebaa-5a58-9d45-70ecdf1792fa,865f5011-5b7e-5810-85d5-63c582ea12bf,6aed20e7-7783-549b-8c58-ba167a441fdc
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Postn-cre;Nf2f/f,animal_models,Experimental Usage,ce87d483-fde0-5e9b-a41e-ff5846fe2c8e,95f1082d-f96e-5e7d-8f17-7f4a01bed966,2b37cdeb-3836-52bd-a2a5-a229d9b507b0
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,DhhCre;Nf1f/f;Luciferase,animal_models,Experimental Usage,5208bfbe-d84a-5ceb-9bba-e51d783611a9,534364ec-5bd4-5066-8aab-1b44350472e7,2f569e31-8ff7-54e8-b684-176b4df47f50
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,Tg(U6x:nf2a/b-4sgRNA),animal_models,Development,ac5e71eb-a1cf-59a1-aa60-2fa769ec91fe,4ae7a300-d8f1-5cab-815b-f1652288fa55,40149ff0-d3d4-5803-bd93-aa74eca79655
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,NF1 R1947X minipig,animal_models,Development,99934420-65ee-55dc-9b07-58dc75fecedd,8509814f-0af6-5405-a0d5-f4686bfdd03c,2f1c5933-8ac9-5f7d-a7e1-60f4eded55c2
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,TetOff-Osx-/-Nf1,animal_models,Experimental Usage,e292cfbe-34d0-5d88-9bc7-af3ad3132150,98f04c40-6c31-53bf-a60f-ca873e104087,61dad128-c400-5e13-b462-a5c01a5644b6
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Osx-/-Nf1flox/flox,animal_models,Experimental Usage,68578e16-2afd-531c-a2a2-13f00a013418,98f04c40-6c31-53bf-a60f-ca873e104087,61ef5af3-9ee1-551b-a8d2-4b6cbee11331
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"Osx-tTA,tetO-cre;Nf1flox/flox",animal_models,Experimental Usage,0b4a4fed-92c9-540a-9f2f-4f715dc4a9ff,98f04c40-6c31-53bf-a60f-ca873e104087,4f21943c-ea3d-5020-849d-053e3e34536c
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Nf2+/-,animal_models,Experimental Usage,f255a636-4154-5b53-a021-90192970708f,a0df1bca-5f35-5ebe-a57c-3c083dd25c09,54f66d81-ea33-5c3e-b5c9-763b915539d1
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,hGFAP-cre,animal_models,Experimental Usage,28711436-20a9-5e6b-b06b-adef8a9e259a,478f386b-2215-5d9d-8a28-7f21227fd667,f3355321-fa18-5f7e-8f14-d892385d821a
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Math1-cre,animal_models,Experimental Usage,f82130ac-e9cf-5e04-80f6-cebc66a5f44b,478f386b-2215-5d9d-8a28-7f21227fd667,fdfe318a-0b2d-54d2-87e4-66a0f4e6ad04
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,L7-cre,animal_models,Experimental Usage,b8cc61ec-41e3-53b2-872a-6f774b01c0ba,478f386b-2215-5d9d-8a28-7f21227fd667,b9bf1586-64f3-584d-ac39-70ab47e7832d
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Nestin-creER,animal_models,Experimental Usage,617291e8-bdaa-5fe6-8801-dd9e7ec55cfc,478f386b-2215-5d9d-8a28-7f21227fd667,cd685fab-cc29-5bfc-bb21-77237036daeb
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Nf1-Arf flox/flox ;Postn-Cre,animal_models,Experimental Usage,99d8dc8c-8784-57b6-aa47-954c2b6e0897,530910bf-7a1c-50fa-8d7c-5ddf953165bb,0a5050bc-6f25-584d-94ef-06f1f9dd8eb0
PMID:38216123 | PMID:38481529 | PMID:37446790 | PMID:39890807 | PMID:29438698 | PMID:29847659 | PMID:36241865,10.1016/j.molmet.2024.101876 | 10.3389/fcell.2024.1359561 | 10.3390/molecules28135128 | 10.1038/s41598-024-84493-y | 10.1016/j.ccell.2018.01.005 | 10.1167/iovs.17-22588 | 10.1038/s12276-022-00850-9,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,neurofibromin,antibodies,Experimental Usage,cf215f08-ae13-543a-96eb-4907fed24def,038e21c3-f8df-5af9-bcfa-ec044e50e4ad,d724a5d6-8188-536b-bb02-0fc5744ff9e6
PMID:32457840 | PMID:20195187 | PMID:21072183 | PMID:31015291 | PMID:28126595 | PMID:29715273 | PMID:30274821 | PMID:39415595 | PMID:38945076 | PMID:24595234,10.3389/fonc.2020.00687 | 10.1097/MAO.0b013e3181d2777f | 10.1371/journal.pone.0013791 | 10.1126/scisignal.aau8749 | 10.1016/j.ebiom.2017.01.020 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.1242/dmm.050862 | 10.1016/j.redox.2024.103249 | 10.1371/journal.pone.0090853,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.",,Merlin,antibodies,Experimental Usage,5aef6e6a-d334-5dea-8df5-11fde0370440,98f74e04-4fc4-5645-be0a-84ee544d38ce,a18d6751-6837-5aa9-bc05-2697d979a999
PMID:41022755 | PMID:28166733 | PMID:38714355 | PMID:39472976 | PMID:41564118 | PMID:30479396 | PMID:39129390 | PMID:34257279 | PMID:34011935 | PMID:25535838,10.1038/s41467-025-63619-4 | 10.1186/s12864-017-3519-7 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1371/journal.pone.0340183 | 10.1038/s41467-018-07452-y | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.7554/eLife.05151,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,NF1,antibodies,Experimental Usage,c27c1920-63a5-5dc8-939e-7185932312b5,7ed7a85f-ea61-568c-acb4-f96ee5a4e657,d99bdc9f-6321-5c0a-b270-e41d89d883b0
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,NF1GRP-D,antibodies,Experimental Usage,06fa0495-518b-5d9c-b2e1-2eefd85d6094,46a648d0-4916-50ea-8031-8acc47037bac,78627244-ee2f-5a10-8bb6-87e12f15e74f
PMID:33273014 | PMID:38216572 | PMID:19144871,10.1074/jbc.RA120.014960 | 10.1038/s41467-024-44755-9 | 10.3181/0809-RM-275,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,NF2/merlin,antibodies,Experimental Usage,316302d9-60e4-5c07-abcd-886256536c18,27dba626-27cb-5501-9b47-75527dd7b5e8,583fc9c4-ef58-5741-978d-ffdea11fbd88
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila neurofibromin,antibodies,Experimental Usage,19db6ba4-2bba-580f-b9f4-13d21d5482c5,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,e81f19f7-1813-5ec5-b1f3-4a2add294e96
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,human neurofibromin,antibodies,Experimental Usage,52b0b8a1-27ea-5c2b-882e-3b5f609e3e41,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,4021a726-e62c-5ac9-bd49-294673a4204b
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,phospho-Merlin,antibodies,Experimental Usage,05617817-524e-5630-8ea4-3f4e6d5d799c,2d046a17-b787-5b4d-8881-41e4cff9bce0,dbdf1ca3-bf76-5dcf-a6c1-188565ac5a5c
PMID:29715273 | PMID:26219339,10.1371/journal.pone.0196726 | 10.18632/oncotarget.4858,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NF2,antibodies,Experimental Usage,362777a6-2b8f-53e4-80fb-954b81c8c278,3bc56521-79de-5a19-9afb-0e9f4ec6b6b8,0f8afde2-7213-5154-95dd-2d492c56adcc
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,phospho S518-Merlin,antibodies,Experimental Usage,e1e03cb9-d84f-5212-b502-b56e0faf38b9,b50c1286-4736-5b9c-8789-27260a2c74d4,b09845f4-970f-571a-8e0c-e6c8b93e94da
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,neurofibromin/NF1,antibodies,Experimental Usage,2b3c5bdd-7ea7-5d77-b921-1307e2cee44d,91102d9b-3d20-56e0-90c2-ca7bd11b41fc,b3a57db0-d64e-5b53-8556-a3bfc93f6f5b
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,neurofibromin 1,antibodies,Experimental Usage,bf240d56-04f7-527d-8983-4a8796d77cf5,c079a8f5-6f86-5f1e-8b61-d414dade9904,94972c11-296d-52a8-ad10-d805b5b59ff4
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,SUZ12,antibodies,Experimental Usage,1074a6cc-32a7-5288-aeef-3c8289717431,709065cc-0444-5cae-8a57-1ef376c6e992,dd40dcb1-e7b5-5164-8751-dfb0daa65243
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518-Merlin,antibodies,Experimental Usage,5276f563-b27e-550d-9574-7050926b6a5a,107350fd-06aa-5a46-b6d8-3bc0f5fccb45,1b15c6e8-036c-5237-a331-13de48f550e9
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,NPcis cell line,cell_lines,Experimental Usage,538a6c09-0c68-5e06-97e5-c62499037580,4c500643-3c43-5c39-a015-aae7aacba58e,41f3ec49-a3df-56a8-be13-329fac246519
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,BJFF.6,cell_lines,Experimental Usage,012c1bba-22f3-5d7e-91fb-8e5c9aab3ff0,686ba2dd-21f7-5c0f-9c35-4a10134fe88f,3dc7da7a-91d2-56ae-af93-c1cea07d24a4
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Normal human Schwann cells (Sciencell),cell_lines,Experimental Usage,4f16f5f5-aee2-5fb5-8bd7-4939202b71d1,686ba2dd-21f7-5c0f-9c35-4a10134fe88f,0e0df540-0cd5-5dcc-863f-c5726016888b
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,TOP-10F' cells,cell_lines,Experimental Usage,61090e6d-e2af-5d14-9b41-cdcb6fb06c60,478bbb4d-93c5-5026-8762-befa931a28c8,90ede777-afc9-5311-b681-ce6333eae4cb
PMID:38216123 | PMID:40507334,10.1016/j.molmet.2024.101876 | 10.3390/cancers17111852,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,MCF7,cell_lines,Experimental Usage,327ea7a4-a7d1-59d3-a567-a72a446a5a2b,9989dba1-c7ff-54ee-b15c-7a910c7d2c86,7009c225-cd7f-57a0-adb2-d1a86b112043
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox calvaria osteoblasts,cell_lines,Experimental Usage,6c433084-9235-5425-9d1c-2f3b2eb7e996,6b5c6af2-fd8f-50bb-be17-0d6f652bf2e4,2161e9dc-dc78-5518-a26b-b35422575e49
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,DH10Bac cells,cell_lines,Experimental Usage,fc0ee5be-c5e4-5b5c-a91d-1a53c5b5c8e1,c258452c-1dfa-5c05-b2fe-4bec5a756d83,7750e324-2e59-5cb7-ba9a-71dc007bf88d
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,BL21(DE3),cell_lines,Experimental Usage,df99b724-4672-5640-8250-3c2bf844e5d4,c258452c-1dfa-5c05-b2fe-4bec5a756d83,c3833025-8a17-54ac-a1ec-57c9531dd2ce
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Sf9 cells,cell_lines,Experimental Usage,0b4971d8-ea0e-5a4d-8d81-563711c8519e,c258452c-1dfa-5c05-b2fe-4bec5a756d83,5d82da91-d47d-578b-9ce7-5bce5028b878
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Tni-FNL cells,cell_lines,Experimental Usage,9a3ba6b2-3811-54af-803e-dc0ee032ed91,c258452c-1dfa-5c05-b2fe-4bec5a756d83,295395e8-095c-58b4-bd92-9b5178a341a4
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,NF1-null HEK293T cell line,cell_lines,Development,df86f235-3a8d-5802-a9fa-c2edf70aef6c,c258452c-1dfa-5c05-b2fe-4bec5a756d83,0b3cb4ca-5e44-5145-babc-2b10416795c8
PMID:40590220 | PMID:35789380 | PMID:31836666 | PMID:29402968 | PMID:31015291 | PMID:40225167 | PMID:34415582 | PMID:39269317 | PMID:23175151 | PMID:38216587 | PMID:20554030 | PMID:28166733 | PMID:33934112,10.1172/JCI188932 | 10.1158/2159-8290.CD-21-1671 | 10.1074/jbc.RA119.010934 | 10.1038/s41598-018-20894-0 | 10.1126/scisignal.aau8749 | 10.1155/2023/9628049 | 10.1002/glia.24075 | 10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1038/s41467-023-40408-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1186/s12864-017-3519-7 | 10.1038/s41419-021-03716-6,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,HEK293T cells,cell_lines,Experimental Usage,44ef4eb6-738f-5091-8d84-bf9b6a4d2c96,b353d4a5-01db-58fd-b624-0817514dc697,6ba75f31-1687-55b8-a135-05638c896b67
PMID:38201517 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:41036607 | PMID:38203448 | PMID:23535903,10.3390/cancers16010089 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,S462TY,cell_lines,Experimental Usage,fd506874-6121-5299-8b75-cc96fb0e22a5,e5e4fc42-d8c9-59c8-9996-413281f0bac8,906fc06b-68d4-5355-ae14-f8a175ea9cb3
PMID:38201517 | PMID:18367665,10.3390/cancers16010089 | 10.1124/jpet.107.135830,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,iSC,cell_lines,Experimental Usage,cd71be14-23ab-54ad-b8d7-4f0b0fd32429,bd6ba93c-e470-5c04-a4b7-aaddeb4a6996,33501856-51de-5bac-813a-6461cff1afde
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,A549,cell_lines,Experimental Usage,98c037b5-73a4-5061-bcc6-295e28c1f7f7,7d34adf6-d82a-5853-b025-eaf7706fb47c,e2918a1d-a7d4-5193-a0f5-248ecba5c0af
PMID:38201517 | PMID:41022755 | PMID:39269317 | PMID:18367665 | PMID:37246765 | PMID:33658640 | PMID:24824755 | PMID:39129390 | PMID:18413802 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:38216572 | PMID:38203448 | PMID:23535903 | PMID:41036607 | PMID:33032988,10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/1078-0432.CCR-24-1750 | 10.1124/jpet.107.135830 | 10.1093/neuonc/noad097 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733 | 10.1002/1878-0261.13704 | 10.1158/1535-7163.MCT-07-0518 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-24-1053 | 10.1158/0008-5472.CAN-20-1365,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,ST88-14,cell_lines,Experimental Usage,0033682f-db5c-5886-9ece-f671e9f8e2c8,b3beab32-8978-513a-a671-16d5100018a9,733801bc-7188-503b-8116-384c9879b9f3
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,MCF10A,cell_lines,Experimental Usage,5c2fa3b4-fd3c-53cc-9409-b2a264c6fe61,7d34adf6-d82a-5853-b025-eaf7706fb47c,7d3dba55-ca50-511a-be1d-8470c1224b70
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,murine NF2 −/− Schwann cell line,cell_lines,Experimental Usage,843f7d67-baca-5011-acff-db0f5d3a2b92,0f37a1ae-fd2e-541b-92ae-1ba0d99e4798,fb87168e-a32f-5220-b2d2-5464417de4b0
PMID:21111000 | PMID:38216587 | PMID:30617350 | PMID:30274821,10.1016/j.jneumeth.2010.10.021 | 10.1038/s41467-023-40408-5 | 10.1038/s41596-018-0105-7 | 10.1016/j.ebiom.2018.09.042,"A novel imaging-compatible sciatic nerve schwannoma model. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.",,HEI-193,cell_lines,Experimental Usage,86bbf430-0f57-5835-8110-b0798d6a2c5c,2fc84107-09e8-5afa-9f43-5e278a8e7833,30ff5a2c-69e6-5a5f-b705-6ce3ecdda69c
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF05.5 (mixed clone),cell_lines,Experimental Usage,2ccdbdb7-7f05-500c-9211-c0073f40b692,83d66cb2-9d6d-58a3-b729-7fe36f92996d,e772bcb6-4a3b-5dab-84bd-2f8343f4d285
PMID:35741605 | PMID:40723243,10.3390/brainsci12060720 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 (single clone),cell_lines,Experimental Usage,b1bb28fc-4b2d-58ac-b524-cfcee2d60382,791b55a8-ebf0-5338-90ec-7e4247fe2be8,0fc4cc7d-3427-5f20-a1f6-b3bf0db9da74
PMID:35741605 | PMID:39129390 | PMID:40862755 | PMID:36689660 | PMID:39061138 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.1073/pnas.2208960120 | 10.3390/cancers16142498 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF95.11bC,cell_lines,Experimental Usage,b700d907-13e1-549d-af02-554cf5088877,94207a39-7a08-590c-896d-42f99a72a145,decace9b-a0ae-5143-9331-06a492b55a5b
PMID:35741605 | PMID:33934112 | PMID:33442015 | PMID:38136356,10.3390/brainsci12060720 | 10.1038/s41419-021-03716-6 | 10.1038/s41591-020-01193-6 | 10.3390/cancers15245811,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.6,cell_lines,Experimental Usage,1e3f51de-688a-53e3-9cc8-d010c17bfce1,ff4f64c0-5425-56e3-88a7-d11a8dda70e8,c95563a3-6943-5a33-ad3c-23b1c509a267
PMID:35741605 | PMID:39129390 | PMID:38136356 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cancers15245811 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipnNF95.11c,cell_lines,Experimental Usage,f3356be0-97d0-5f39-9d1a-3a4bee972e51,2722b3bd-00da-5a71-aba8-aa0f57f9745c,bd2c5a12-209e-5172-bb51-6a3eccd64580
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,COS-7,cell_lines,Experimental Usage,38f3ea14-4324-5fff-a9f6-c36fc2ff4cbc,e687328f-6e1a-58b4-bed5-5f4a0380626e,6f3ef438-16e5-5ded-b91a-e0b3f8086c69
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Nf1-/- mouse embryo fibroblasts,cell_lines,Experimental Usage,374c9e93-7302-51f6-bc1f-50ce7d917501,1b4fed4e-2702-5565-9589-44897e2816d1,ffd2b57e-8920-5631-9047-ef384b8e5fd3
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,T265-2c,cell_lines,Experimental Usage,190a393b-59f8-559a-bf42-5cd883ae3b7b,f9a8cd1f-d060-5b25-bf25-ae5442ad2960,bcd30b69-1586-5ceb-abe5-4b9e19466fe4
PMID:24824755 | PMID:20049725 | PMID:32642733 | PMID:18483311,10.1371/journal.pone.0096733 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,90-8,cell_lines,Experimental Usage,048e2b9e-6d4a-545f-a50a-73baea5ee75a,b98b7ee9-8359-5e60-8021-0d8bb94e0657,2667d8da-de63-5e85-9ae9-59d00058b48d
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF96.2,cell_lines,Experimental Usage,04382355-1898-5f73-8e52-2fdb2b68f4f1,707e2147-f592-5c83-8199-9b2176b31b60,c1d72c0c-37a9-5f45-9603-2afdf01969a8
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,NF02.2,cell_lines,Experimental Usage,1ad45263-53f7-5870-8fe4-5688385b3f58,78e760b5-d272-598f-a6e5-099b332c1574,dc65eb71-c590-5a4f-b241-ddd888075c31
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF94.3,cell_lines,Experimental Usage,d9032e70-87df-5ddb-bd91-6028ef24a955,707e2147-f592-5c83-8199-9b2176b31b60,3273be64-f8a9-5cdc-a01b-c94dc69dd748
PMID:33673681 | PMID:30531922,10.3390/cancers13050999 | 10.1038/s41591-018-0263-8,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,HEK293 cells,cell_lines,Experimental Usage,bca5ffd7-15dc-5a3d-884f-6dcac4542385,3177bcf4-8f19-58e6-88df-27967762f66c,b42a808f-f6c3-5ac1-84a6-d17b6c558b6e
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,LLC-PK1 ATCC CL-101,cell_lines,Experimental Usage,9a40c7b2-ae73-515f-b1fc-f716f611d305,5bb76bf8-8dce-5b7f-b68e-e0ad4ccd0e21,9111df47-6a9a-5c46-b54f-0661751f2960
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,MiaPaCa-2,cell_lines,Experimental Usage,fd287e79-df75-5240-beeb-e1aa4871699f,2fb7a8fd-ef53-5a4a-bea5-95f0535c0ee9,6cc5b753-3c9d-58f2-a150-c8734abe04eb
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,PANC1,cell_lines,Experimental Usage,e940c900-7997-54c4-b841-922258573edd,2fb7a8fd-ef53-5a4a-bea5-95f0535c0ee9,26bcc0da-c9e4-572f-b1a0-03894867affa
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,BxPc3,cell_lines,Experimental Usage,49128c01-5261-56f3-896f-0b8f23151154,2fb7a8fd-ef53-5a4a-bea5-95f0535c0ee9,e4854530-f8ed-5268-9ebc-1d61d77ab603
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,AsPC-1,cell_lines,Experimental Usage,c537fc59-db14-5407-a145-a822b96e672c,a64e9b65-068b-5d68-8369-dcfe8e1f7a64,d1386129-d898-53a6-97e0-9c5b440df5e9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,HPDE H6c7,cell_lines,Experimental Usage,f615894e-76ad-5066-a46d-e20154fe8a07,a64e9b65-068b-5d68-8369-dcfe8e1f7a64,ac9fd66a-4a56-56c7-935a-f6521a4ccbe5
PMID:33273014 | PMID:28126595 | PMID:26219339 | PMID:36148553,10.1074/jbc.RA120.014960 | 10.1016/j.ebiom.2017.01.020 | 10.18632/oncotarget.4858 | 10.1093/brain/awac342,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Ben-Men-1,cell_lines,Experimental Usage,f6632be5-e021-5bd7-a3ef-0f32a0f58c72,41be0a55-e0ba-582b-977b-c5794cc378b4,6715cb90-7319-5955-bd46-b1d21da7f08f
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,AC-CRISPR,cell_lines,Experimental Usage,572eb7ee-a773-5990-9f3b-f8ece87f5aa0,5bc1107a-318b-5d73-8caf-9f2515e10a78,278b42a5-7b40-5c9d-bf08-b0a48350860b
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MN1-LF,cell_lines,Experimental Usage,99b0b9d5-4d54-5037-9187-f49a17a21003,5bc1107a-318b-5d73-8caf-9f2515e10a78,5b905bbc-dcc8-56fe-940b-3441008c4e1e
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,H358 cells,cell_lines,Experimental Usage,3d9c0432-7452-5404-b6e4-edbf2c6080f1,b6f968b6-b92b-5b4b-b213-c0620217ce52,012f42c4-0aaf-56e9-a583-60a3a15266fa
PMID:41022755 | PMID:32383545 | PMID:33658640 | PMID:38502231 | PMID:23328114 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:41001593 | PMID:32948135 | PMID:37410426 | PMID:23535903 | PMID:35511749,10.1038/s41467-025-63619-4 | 10.15252/embr.201949117 | 10.1038/s41416-021-01270-8 | 10.1172/JCI176748 | 10.18632/oncotarget.793 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947,"Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.",,S462,cell_lines,Experimental Usage,86a2bdd9-4bf3-50e4-aadc-b562b0f8f798,e4df9329-1709-5fb5-a8c7-cb1f615d37a2,61206236-fde5-5b73-b1d5-307009cd177c
PMID:38502231 | PMID:35393510,10.1172/JCI176748 | 10.1038/s41418-022-00991-4,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,cis MPNST cell line,cell_lines,Experimental Usage,314c51dc-6416-53ce-9c11-fe47bc9f7510,19e0e99d-6e58-5315-a78e-645b7d44c97a,09cb80ef-92ae-5763-90f6-4c104818f6e2
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,HTS-Luc MPNST cell line,cell_lines,Experimental Usage,fd35f3d3-b462-510c-b88b-31d2f0d3d056,b6f968b6-b92b-5b4b-b213-c0620217ce52,384bd83b-5359-5a91-91a2-c02ea3eb23a3
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,pNF9511bc,cell_lines,Experimental Usage,41280959-47ce-5319-9287-1067f97e9ee0,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,5caa5d42-6319-50cd-aebb-631e7ec3962c
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipNF03.3,cell_lines,Experimental Usage,57c76eaa-c9e1-5eab-9478-e052f643e673,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,99748120-583f-5350-b9f8-cb1231cf4a6b
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipn023λ,cell_lines,Experimental Usage,492bff71-6369-54a6-b419-99697235f008,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,1cec00ad-018a-5e7e-ac4c-9ee63ce76f25
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,RHT92,cell_lines,Experimental Usage,019f78bd-50a5-52d6-b3a5-bc4b2efdb036,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,16a60b64-483c-518a-abae-07c189adef81
PMID:41022755 | PMID:38714355,10.1038/s41467-025-63619-4 | 10.1158/1535-7163.MCT-23-0510,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,LN229,cell_lines,Experimental Usage,46557035-5836-5379-928a-59a9d6acb90a,33442106-f54d-511d-a3e9-b2b6e36e1666,c865f818-8228-57eb-84d6-b7a24593eab1
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,2V6.11,cell_lines,Experimental Usage,e63793b4-ebec-5925-9c76-63d4445d4c4b,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,a4765cbe-ba30-544b-b731-3818d93f6b5f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,FiPS,cell_lines,Experimental Usage,f4acfd93-16bd-5d68-8e3c-82b779ff6677,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,4b532828-56be-5d3a-8a2f-0e288c8acfcf
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_lines,Experimental Usage,b0ff429e-8a6f-5fed-af9b-2fae9b213723,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,e2b415f7-c74a-5407-92da-98802525b0d2
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,3PNF_SiPSsv_MM_11,cell_lines,Experimental Usage,abeb8b06-79c5-52cd-9a0b-a2d74b890803,e5ab36b3-2d18-5286-88eb-01a7d6a53d9a,3b3f7ea5-3fb3-5674-9f21-01157693cfc0
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M724,cell_lines,Experimental Usage,6a02a896-ce58-529f-ace1-3a460c94c354,e68a9879-208f-5644-9385-650c8f87ffaa,c5e9a426-fca1-5185-a52f-ddccbacfdd9b
PMID:39269317 | PMID:23175151 | PMID:29438698 | PMID:40025578 | PMID:36322658 | PMID:35511749 | PMID:32642733 | PMID:38216572,10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1016/j.ccell.2018.01.005 | 10.1186/s40478-025-01965-6 | 10.1126/sciadv.abo5442 | 10.1158/1535-7163.MCT-21-0947 | 10.1093/noajnl/vdz061 | 10.1038/s41467-024-44755-9,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF96.2,cell_lines,Experimental Usage,63df939c-c063-5641-a011-a4e30b80e8f6,ddf45ed4-5193-54f3-aebf-91389f210a42,14909473-2fb4-5ed1-b829-ff132be20653
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M1,cell_lines,Experimental Usage,7ccef395-a9a6-5b50-a5dd-52650953b1ff,22d07f30-bf9c-5a85-8a38-bb244a7e8920,58572cd5-257d-5a91-bce4-c2b350c55e81
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M3,cell_lines,Experimental Usage,d1372521-1a0e-5252-9cc9-6ed06082ed33,22d07f30-bf9c-5a85-8a38-bb244a7e8920,0ba2fe44-41b5-5a53-a55e-9b75fe5f1d68
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M4,cell_lines,Experimental Usage,86c3a4a3-451e-503c-b576-de5a23f7024c,22d07f30-bf9c-5a85-8a38-bb244a7e8920,05ae7018-8e02-56bf-9b5e-d339b1e441a0
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M5,cell_lines,Experimental Usage,73e593f0-6a98-5455-97da-c04e6a3e5247,e68a9879-208f-5644-9385-650c8f87ffaa,cd2834e1-9e2b-5a0b-9a96-6836b5a86c8d
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M6,cell_lines,Experimental Usage,af94aae3-ae53-5479-95e1-1a739d18d376,22d07f30-bf9c-5a85-8a38-bb244a7e8920,d81d9712-f258-51b8-8278-78cc50900055
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila Schneider (S2R+) cells,cell_lines,Experimental Usage,90d4653a-6211-5b79-ab22-f9e0342f3f7b,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,8b24ba11-5bb2-5389-843f-6aec45ed87f5
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNF1‐KO,cell_lines,Development,a5b09873-7787-59e0-ae69-f074a1eeda63,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,ecc9f50b-8516-53ee-af1b-d0c996ab387f
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,hTERT ipn02.3 2λ CRL‐3392,cell_lines,Experimental Usage,6ef88ab4-ebfe-56f6-b52d-01360d8151ec,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,0d3202e9-a216-508d-bbd3-eff818fc855b
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",cell_lines,Experimental Usage,33327528-e79b-5cb5-b329-98b0b62a7ca5,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,db404bea-0054-592e-8ee9-2d9a343749eb
PMID:39129390 | PMID:40862755 | PMID:39061138 | PMID:33658640,10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.3390/cancers16142498 | 10.1038/s41416-021-01270-8,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_lines,Experimental Usage,1a003de7-05cf-59b0-b787-fe5420236865,d5c8487e-38ac-5451-8059-2e1061fdf107,96120edc-55b3-55fb-a2e0-dd892ef8b39f
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,U2OS,cell_lines,Experimental Usage,b60781ee-616e-5b62-977b-fa06138d80ec,9093c9f0-5b58-57fe-9204-919ae6dfd180,13cfbf4b-7b85-5529-81fd-0799e3d00ab7
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Human meningeal cells (HMC),cell_lines,Experimental Usage,8b496089-4255-5d2e-8136-b65df7e7cf18,2d046a17-b787-5b4d-8881-41e4cff9bce0,19940322-7115-5e2f-94be-ecc5c28ab7b1
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,lymphoblastoid cell lines,cell_lines,Experimental Usage,5f55b800-890d-5fde-b285-56fb799c33c0,11a0f60f-6dd4-52ae-a20d-8e246bf36c6d,6e020ba9-4b89-51e0-9869-af3bb72e39da
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,OLN93 mouse oligodendrocyte cell line,cell_lines,Experimental Usage,ce4e0ae5-9589-5c8e-a28f-35bf8cfae081,b50c1286-4736-5b9c-8789-27260a2c74d4,aaed50c9-2844-5c59-bfc5-5c78ade18117
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,SC4-immortalized Nf2-/- primary Schwann cells,cell_lines,Experimental Usage,8bd161e7-18cb-5023-9e05-7e0aa5cc80f2,b50c1286-4736-5b9c-8789-27260a2c74d4,3a050b9b-f50a-50e0-82be-af5580a2bcc1
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,RT4-D6PT2 schwannoma cell line,cell_lines,Experimental Usage,d3d3f51d-6a17-57a1-adc2-62412b482f13,b50c1286-4736-5b9c-8789-27260a2c74d4,df57cf04-e722-55e4-9965-40dee2f876d6
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,TC620 human oligodendroglioma cell line,cell_lines,Experimental Usage,8b325c8f-a42e-5e79-ba57-e871daa0d6c1,b50c1286-4736-5b9c-8789-27260a2c74d4,520833a7-34e9-5a8b-aa08-c19e79dc0612
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Normal human Schwann cells (NHSC),cell_lines,Experimental Usage,23d904d8-da65-5ade-bb4d-51aab1204ab8,53016f74-b535-58ed-81db-9e75ae05610f,6793aaa0-c35a-5164-83b3-10692471e87a
PMID:24509877 | PMID:18413802,10.1038/onc.2013.506 | 10.1158/1535-7163.MCT-07-0518,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,MPNST cell lines,cell_lines,Experimental Usage,574102c5-ddad-58a7-834b-05487b124c83,9c629486-8cd2-500c-b3de-9327ec882a45,5512de2b-3b60-5754-9efc-425090e750d2
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST 88-14 cells,cell_lines,Experimental Usage,52cf5c88-3ad1-52d1-aa12-79bba90b3225,53016f74-b535-58ed-81db-9e75ae05610f,0bb4db3d-95b6-5372-808a-c6704a2625bd
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST S462-TY cells,cell_lines,Experimental Usage,4b028900-fb28-562f-b1cc-8dbf50d2f8b5,53016f74-b535-58ed-81db-9e75ae05610f,73a99a79-c7e0-561a-b064-359aed15bc81
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2884 cell line,cell_lines,Experimental Usage,71cff6c1-8ec9-5099-89a3-397085049661,054493fd-b855-50ad-84fe-6e16e382d49a,30a3a0f4-30d6-5d2c-a8cb-3f231d2fe2a3
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2885 cell line,cell_lines,Experimental Usage,bc2664c0-7bf0-520c-96e7-8429fac9a701,054493fd-b855-50ad-84fe-6e16e382d49a,3047a0ba-ac89-58cf-800e-4e7c1680e207
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,hTERT NF1 ipn02.3 2λ,cell_lines,Experimental Usage,6abba05c-adb9-5b1f-ac73-f48b67967410,dedce255-85c0-5393-a506-95313062ed5a,9f3e8e84-4dae-5b7e-a500-10d297c4a08e
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ipn95.11bC,cell_lines,Experimental Usage,b966c9ce-eaf2-57c8-92f0-22976fbc3761,dedce255-85c0-5393-a506-95313062ed5a,3a974d02-5dd6-52a3-b71c-918c878d314a
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,MPNST642,cell_lines,Experimental Usage,474fa9fc-c25a-50b3-bb6a-0b301afbeb18,dedce255-85c0-5393-a506-95313062ed5a,64ee8b55-8367-5ff0-acb6-49e2897955e6
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:41001593 | PMID:38203448 | PMID:32948135 | PMID:23535903,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1080/23723556.2025.2561292 | 10.3390/ijms25010277 | 10.1186/s12885-020-07397-w | 10.1158/2159-8290.CD-13-0081,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,T265,cell_lines,Experimental Usage,05749c41-a723-5edf-89e2-edc2f16df3e6,900138c9-969b-5daa-a7fb-60a1496be5a0,33995551-b2f8-566f-bbba-cb638a12ba6b
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38203448 | PMID:37410426 | PMID:23535903 | PMID:35511749 | PMID:33032988,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.3390/ijms25010277 | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947 | 10.1158/0008-5472.CAN-20-1365,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,STS26T,cell_lines,Experimental Usage,6ad48975-f47f-5437-9a64-fc771304425e,282907f0-4989-535e-909b-75c5db524d89,857f7dbe-27ac-5f60-80de-aa12f7080a95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,ipn97.4 immortalized human Schwann cells,cell_lines,Experimental Usage,fa6cae54-e24f-56ce-9f83-5927539d57f6,32570180-ce07-5150-89a3-8d34b6c92f2f,1a438aef-29b2-56c9-bf41-08b8b51329fa
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Schwann cells,cell_lines,Experimental Usage,d82f52f1-76a0-5fc2-bdc9-fdc6f8ad5c0d,d2f07474-f43f-50f7-abc1-ecf76627be65,45e82643-6f9d-5f5a-842e-b288e3703d7f
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,optic glioma cells,cell_lines,Experimental Usage,f4cd1219-2dab-52c8-8fad-72ab650392b9,9a3e4289-b548-5076-830c-a47d7c0f1c37,6d101a5b-0f0e-5148-91f6-8e033fd471ce
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,HSC1λ,cell_lines,Experimental Usage,2d143e87-aa13-5a92-a338-e171a80d4359,7600a9af-bd48-5236-8d3f-c9d27c202e7e,16b9df1e-b09c-5691-af15-0464246c2942
PMID:37164978 | PMID:38136356,10.1038/s41467-023-38432-6 | 10.3390/cancers15245811,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF06.2A,cell_lines,Experimental Usage,3c9cc836-9756-5f2f-a1fc-a8939038e7bf,5b423b36-927d-5301-a30b-a9903960b9a1,57fd30a0-521e-59f8-80f1-ddfe31e9c772
PMID:40590220 | PMID:36420221 | PMID:32383545,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.15252/embr.201949117,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,HeLa cells,cell_lines,Experimental Usage,cdea1d65-c600-5ecf-964f-7529ce90f799,3ce555a1-bd49-5897-9394-b33a20baae5a,db3db0ae-5a93-506d-bef3-17718bbb4158
PMID:32383545 | PMID:37446790,10.15252/embr.201949117 | 10.3390/molecules28135128,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,C2C12 cells,cell_lines,Experimental Usage,903c378d-610f-5996-9dcb-d7155a487957,5ac74644-2813-50eb-bedc-5cf17b0e311c,ae2135e1-4d74-5f96-b026-ec9873d49eb2
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-1 hiPSC line,cell_lines,Experimental Usage,bd752905-90af-5cd3-9b6e-12eca094bf7f,e76ccf41-1253-5aa7-9908-903cb8bf2fcb,1760a885-37db-59e7-a79d-b0749772a6d8
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-2 hiPSC line,cell_lines,Experimental Usage,dd74c6b9-b466-535a-8640-9350064228c5,e76ccf41-1253-5aa7-9908-903cb8bf2fcb,f06517b7-580b-5060-8de6-1918e745f09d
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-1 hiPSC line,cell_lines,Experimental Usage,f1183dca-e9aa-5e92-a239-dd366aba74ed,e76ccf41-1253-5aa7-9908-903cb8bf2fcb,00a4afb5-a6d7-5227-9041-942a7781cddc
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-2 hiPSC line,cell_lines,Experimental Usage,d5df9926-2129-5646-ae18-421c4385ecf8,e76ccf41-1253-5aa7-9908-903cb8bf2fcb,6ea53b58-c0ec-519b-8b9d-eff75a906795
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,LUVA cells,cell_lines,Experimental Usage,81e526a4-e31c-5afd-ab73-f7b56c3af2dc,91102d9b-3d20-56e0-90c2-ca7bd11b41fc,b55bee8c-2e29-594b-8678-d3325c18143b
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_lines,Experimental Usage,90a06c35-50fe-513d-bf0e-89731418b211,71ed2e14-be02-54de-84ca-c74fd4e77090,0db1eb5c-a4d2-5c75-bee1-c3f9e4c42cef
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",cell_lines,Experimental Usage,2a2f302d-fa9c-56a5-a88e-7f1113b66fab,71ed2e14-be02-54de-84ca-c74fd4e77090,318750a4-ea8b-515a-bd7a-76c3784c36c3
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF37,cell_lines,Experimental Usage,0a136c29-aeca-5697-959a-f03a9edc0be5,9a35cdd4-3f58-5586-be89-dc1a46137c1f,9fad9960-2016-5753-9866-0c939222bcd5
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF87,cell_lines,Experimental Usage,0191b298-fe4f-59ff-99f8-c7afc9036f2c,9a35cdd4-3f58-5586-be89-dc1a46137c1f,9e1f94af-229c-5c37-aabe-d5db89723c2e
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT10,cell_lines,Experimental Usage,9483b3c1-8264-5a9e-8b66-4f722d18f2e2,9a35cdd4-3f58-5586-be89-dc1a46137c1f,5b5c5912-0cf3-5631-8ba2-1c2e4a45c1ea
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT11,cell_lines,Experimental Usage,cc700350-6291-574f-9b7e-c1cbb36e9b41,9a35cdd4-3f58-5586-be89-dc1a46137c1f,d408830f-dc82-574d-b204-559ba820d989
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT12,cell_lines,Experimental Usage,49c07d0e-82da-5059-bb6a-ba0193fcfba8,9a35cdd4-3f58-5586-be89-dc1a46137c1f,9af1d3b0-91b2-5461-af1d-209ef38629f4
PMID:29438698 | PMID:38216572,10.1016/j.ccell.2018.01.005 | 10.1038/s41467-024-44755-9,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF02.2,cell_lines,Experimental Usage,955dfcd3-2698-59b4-b5b3-5f6944cad6b7,c20ac4b3-1261-5b05-a468-6dc50cd917b5,7d07e1d2-fe8d-57ac-9d87-7f4040b54729
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,TM-31,cell_lines,Experimental Usage,62dac117-64d1-551c-abf2-4c6de8de1240,10088f76-3416-594d-a08b-efff5ad7f29f,274be0a0-e9df-5860-8892-72cb9887d099
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,LN319,cell_lines,Experimental Usage,86f678c3-e3af-5f70-883d-15bcfe629591,10088f76-3416-594d-a08b-efff5ad7f29f,299a9e12-545a-533a-9848-39f085721fd1
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,17,cell_lines,Experimental Usage,4baa364e-35e8-54d7-88a4-e29544f403bf,10088f76-3416-594d-a08b-efff5ad7f29f,35158f01-4e4f-5a4c-93cc-058b269bf7ce
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5653,cell_lines,Experimental Usage,2568cdcd-2131-5622-a698-90fc2124729a,10088f76-3416-594d-a08b-efff5ad7f29f,9b0a4c5f-a9d1-5418-96cc-961164037e28
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5746,cell_lines,Experimental Usage,5fac1d87-4ef8-57e0-b99c-250849f13bec,10088f76-3416-594d-a08b-efff5ad7f29f,7ab1a9a6-fbdd-5c18-8942-e94bfdf6ef28
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",cell_lines,Experimental Usage,a875a7ad-cb70-5316-bb8c-94133f1ebe4b,2f4c6836-84ea-5091-b651-3c23a073ed61,02846028-6445-5e63-bba0-8ac632254763
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,LS141,cell_lines,Experimental Usage,2885cd49-000f-5f44-8b43-138db683a407,9d2773ac-d446-5d7b-897e-26b3f4b5ff33,66c70328-85a9-5e0d-8042-37528bd5f087
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,DDLS,cell_lines,Experimental Usage,257d5d35-a7e3-5fa4-8237-f80a3d6fed3c,9d2773ac-d446-5d7b-897e-26b3f4b5ff33,064964d4-f8ec-5add-a40c-3abad4aa78d1
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,Human Schwann cells (HSCs),cell_lines,Experimental Usage,0f02810e-f2d4-5945-b624-8e79905f6e29,abf6a2b1-3b0c-5df8-a16e-d264bd0469bc,12895209-2ffe-54b9-99eb-02d7c91ae8e6
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,RT4-D6P2T schwannoma cells,cell_lines,Experimental Usage,fe53f850-ce21-5f1d-99aa-78fb8d3d2241,abf6a2b1-3b0c-5df8-a16e-d264bd0469bc,7f248fad-3eba-5240-9e11-aae2a861d9c8
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,LN428 human glioblastoma multiforme (GBM) cell line,cell_lines,Experimental Usage,3947e66e-3f77-5966-9de5-c3a2679d65dc,d58c9faf-ef15-514d-8927-2bf7edb94535,7381a36e-0cd3-5b7d-9b6e-553506c81e7b
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,BL21(DE3) Star,cell_lines,Experimental Usage,33627f84-10fc-5866-b81d-2d2e9c3e3677,0cdefd2a-bf11-5ffc-a43b-0f263626c7a8,d1c9b566-0c52-5b23-9fce-761eed670430
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1-null 293T cells,cell_lines,Experimental Usage,27965ae8-205d-5c47-8335-3c19581af2a5,432d2a83-2b14-554a-9a0f-b50e512ce189,bc896f98-e6ed-578c-b02e-d5c68001d49d
PMID:28392281 | PMID:34065204,10.1016/j.expneurol.2017.04.001 | 10.3390/ijms22105367,Human stem cell modeling in neurofibromatosis type 1 (NF1). | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,mouse embryonic fibroblasts (MEFs),cell_lines,Experimental Usage,5857a30c-ed43-5921-a5c7-fab7a70ff98f,f5107a91-c336-5f89-9f92-2d40d67baf62,441c9238-67d2-506c-a607-419d96a3b689
PMID:38000020 | PMID:38127282 | PMID:33032988,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548 | 10.1158/0008-5472.CAN-20-1365,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-002,cell_lines,Experimental Usage,ef89c35f-e139-504b-b2e8-5b90cca54508,5b16d8ef-06e1-59a4-880c-583355142089,0e1ef12a-918c-5632-b5ca-6a8d3bff1105
PMID:38000020 | PMID:33032988,10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-031,cell_lines,Experimental Usage,743f6c15-2aa4-5567-bc86-3e68d3830435,172c6658-7071-5a13-b5d5-c1aa73f94225,abf9906f-e801-5772-98d1-23f1ab670210
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c,cell_lines,Experimental Usage,afae6a0c-dfa3-5a0c-94ca-ff00c772a872,f9a62cfb-88fc-55b1-a269-f3fe2b0da09f,4a0443c7-a980-5c3b-9c83-9f42d09127f6
PMID:38000020 | PMID:38127282,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-103,cell_lines,Experimental Usage,92def16e-3799-50ba-9dd0-92ddb4be5fdc,c8577ef1-4b6e-5614-a1e1-f641dccaa233,0d57eb6f-37e3-5c9c-8096-c8703db37579
PMID:23685747 | PMID:41036607,10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,iHSCs,cell_lines,Experimental Usage,1af2e229-a130-572b-9808-e12b1e9b5b49,08520740-240a-51d5-a9c6-49b69795c63c,eb060f63-0452-520f-a98b-5e20770c00a3
PMID:23685747 | PMID:40025578,10.1038/ng.2641 | 10.1186/s40478-025-01965-6,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,K562,cell_lines,Experimental Usage,93f264f6-6765-5bc0-95a4-74103bb85677,333ef200-8c2a-5bd6-a34d-2a60fd624e19,eacac9ed-5266-56f0-9d8b-38b1b0c9ba6a
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2a,cell_lines,Development,192af261-988f-531e-8b19-a603471cdc17,f46eefbc-e6b3-5e52-aad6-5a5e55ed9c83,c5eab181-010c-53e7-b11e-29b4c9ae3167
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2b,cell_lines,Development,3209f7cb-c096-5e79-bff7-8af9237c0802,f46eefbc-e6b3-5e52-aad6-5a5e55ed9c83,05069634-3b1d-5ad3-9c24-0d974e469302
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF98.4d,cell_lines,Development,7457d1bf-1e64-5c2e-bcde-e2b0667d6b59,f46eefbc-e6b3-5e52-aad6-5a5e55ed9c83,6e93c382-29ba-548e-b7cc-c863cd81b98d
PMID:40025578 | PMID:25026211 | PMID:26219339,10.1186/s40478-025-01965-6 | 10.1016/j.ccr.2014.05.001 | 10.18632/oncotarget.4858,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,293T cells,cell_lines,Experimental Usage,b78f8884-bd37-5fee-8c76-2e13d30c9cd2,43db9e2f-6120-5afd-8e9e-f475af74c6c8,e8626696-31a8-5ce5-85ba-eafdf85a9081
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HFFs,cell_lines,Experimental Usage,3534ebb2-9c47-522f-9686-cfe5afc44c91,3cb7caa2-4fba-5902-a922-3fa2688ef9a5,c4cd60d8-b8d3-5e23-8169-e9f9aa19c889
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,NCI-H266,cell_lines,Experimental Usage,33442cb2-089c-5620-968a-00ca444be330,3cb7caa2-4fba-5902-a922-3fa2688ef9a5,6e520e64-5b89-505e-b1c6-b07c0d2d47aa
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Neurofibromatosis 1 fibroblasts,cell_lines,Experimental Usage,8486be79-363b-518c-9e84-290bde4b22fd,e10a00cf-23af-5d2d-b4c3-2a0a864a6729,d801b6e8-d449-515a-93ad-5d8e0133ae7d
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01,cell_lines,Experimental Usage,eb7dda5c-8f8e-5f30-b105-320cc908ec2a,294191e1-49c3-569a-8ac9-0d1eff798717,40210d2d-9336-51b4-b9db-f804f59a70bd
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-08,cell_lines,Experimental Usage,bb2a3104-9f02-5f44-ab2c-ec1f27d70e0c,294191e1-49c3-569a-8ac9-0d1eff798717,8d54897a-5c5d-523b-b534-4b2e8aa80286
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-9,cell_lines,Experimental Usage,a5228431-f6f1-53dc-b5d9-16d3cea59233,294191e1-49c3-569a-8ac9-0d1eff798717,17bbbdea-39a6-5035-9fab-edd9c988df07
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-PSS,cell_lines,Experimental Usage,a110d1df-a069-5abf-b579-358893b00509,294191e1-49c3-569a-8ac9-0d1eff798717,8381baf7-b584-5734-864d-6990e37ca550
PMID:32642733 | PMID:35511749,10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-21-0947,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-Sch-2,cell_lines,Experimental Usage,cc1f89a8-9051-5adb-b251-8bf2149dc958,62e0eeb7-6297-5cae-84f8-06aa77473686,435d01d8-e503-5fba-a288-26f4c5a7c143
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Human Foreskin Fibroblast (HFF),cell_lines,Experimental Usage,04d967cc-518a-56b1-a198-1a76ebaf8fba,294191e1-49c3-569a-8ac9-0d1eff798717,ecdf2706-b174-572d-9103-02029186533d
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,ipNF95.11b C-RFP,cell_lines,Experimental Usage,85c73653-b123-527b-9781-dfe9189694d0,1753ccb3-b4f9-5369-9ae3-20e48a267351,f81032de-94dd-5492-98a8-571cd6727fa4
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC007-hTERT,cell_lines,Experimental Usage,26f10202-daf2-5ab4-9c0b-f19da878e72b,ce1cd2ca-32f2-5e47-b4c5-4c774e788b06,23d9a69b-945e-538c-8e8b-52b9b79983d0
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC028,cell_lines,Experimental Usage,7c5ccc6f-b02e-5888-b77c-9c9d7ff37582,ce1cd2ca-32f2-5e47-b4c5-4c774e788b06,38bed69c-8c07-53f1-aa00-08c26becbb26
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,U87-MG,cell_lines,Experimental Usage,d3889358-1278-598f-98c1-75d6aef7a702,709065cc-0444-5cae-8a57-1ef376c6e992,9bffcee2-110a-5f30-a83f-5349091ab434
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Meso-33,cell_lines,Experimental Usage,bb56b2bf-e719-55ce-9dfa-a462bc5f0d80,3acd29a3-88ef-5a6d-b445-f6cbd97f51fb,5d1eb25f-d9d0-56d8-9d0d-c231ac92a03e
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,FC-1801,cell_lines,Experimental Usage,1df19482-fd66-5673-96c3-09a923697756,3acd29a3-88ef-5a6d-b445-f6cbd97f51fb,89d138e5-0f23-56da-90b7-17213e525529
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,NIH-3T3,cell_lines,Experimental Usage,ff1e40f6-df36-583a-aeda-c092f9728527,f6509b53-53ea-5ba7-a1ef-e70af297aae1,901d010a-831b-5221-a14a-3fd465e9c1de
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,φNX packaging cell line,cell_lines,Experimental Usage,68adfc33-3b32-595c-8ea7-cdaa6162c8de,f6509b53-53ea-5ba7-a1ef-e70af297aae1,e569d9f6-0608-5741-ba68-3259feacc272
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,H1838,cell_lines,Experimental Usage,77058785-e4bd-56ef-9f55-ec0c372bed2b,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,d96837ab-ca54-5f40-afd9-0b7ede0f172f
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,WM3918,cell_lines,Experimental Usage,6bca6e70-946f-5bf4-8dfd-9cfc7d0fdb31,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,2286ee1a-9330-5bf4-ab3c-c46362e5d070
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,M308,cell_lines,Experimental Usage,069c4d21-568b-5f91-8796-79a7a6fd63c1,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,4f4adb1b-8529-58fe-aa4c-3a99cf63acf0
PMID:18367665 | PMID:33658640 | PMID:33032988,10.1124/jpet.107.135830 | 10.1038/s41416-021-01270-8 | 10.1158/0008-5472.CAN-20-1365,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF90-8,cell_lines,Experimental Usage,2aa743f5-f3d9-5440-bfa2-ea0625954016,f512ab44-d52c-50fb-a04c-dfd351084d34,2859c032-ab81-5e1e-b05c-9043e10e6982
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF10.1,cell_lines,Experimental Usage,1874916e-8cae-5b69-9650-42c0a760e938,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,f6f389ee-1913-5b51-9e9d-60718392f57d
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF11.1,cell_lines,Experimental Usage,221a1a16-fb18-557f-baca-811a8158d0a9,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,6cd8aa27-1517-5cb7-9ccc-c3776d7be0c1
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,K4622 grade II glioma cell line,cell_lines,Experimental Usage,b9598774-e329-5d48-a36b-5c6fb96e685c,3e0eb04b-7803-569a-a47e-de921c5c1775,6b8fd2c3-41d4-52bf-9a7d-1969f1422589
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,HSR-GBM1,cell_lines,Experimental Usage,5362a791-edde-55dd-ad3d-b19c24b70734,e8d2a50b-c332-5293-8552-b94b9d91eb41,762b37cf-abef-5668-ab53-d37ef4a0bcda
PMID:39472976 | PMID:38714355,10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-23-0510,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-520 cell line,cell_lines,Experimental Usage,d7c018f6-c31f-5f62-a31b-9d9d5f75940a,4d015b69-5303-5bfb-a993-34edc61449c7,49c24d32-1f3e-5e44-8337-d5837d36adae
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-0879,cell_lines,Experimental Usage,2ea1769b-093c-569b-a648-1b20215e806c,e8d2a50b-c332-5293-8552-b94b9d91eb41,0d04bfc5-f3eb-58ae-aba5-96690c0cfbfb
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-1016B,cell_lines,Experimental Usage,eb23b275-851d-51af-bd1b-9f1f9ba2396e,e8d2a50b-c332-5293-8552-b94b9d91eb41,02151179-f287-5580-abd5-2ac2cbc4c692
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-136,cell_lines,Experimental Usage,4384d191-e37a-5546-ba1e-6633bf1f371f,e8d2a50b-c332-5293-8552-b94b9d91eb41,82df4dd9-a6dc-5203-920c-ea805bc2b4cf
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,B76,cell_lines,Experimental Usage,4c5ec193-d00b-5c60-a279-f234b62b7dc8,e8d2a50b-c332-5293-8552-b94b9d91eb41,a30cb5fb-b05b-5f83-bb30-996e8fbfc76c
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NGT-41,cell_lines,Experimental Usage,bfe5c5a5-f1c3-55b1-b0db-ee4049107ab8,e8d2a50b-c332-5293-8552-b94b9d91eb41,e9cebee0-b3a6-597f-8b44-15271a6f53a4
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NMCG-1,cell_lines,Experimental Usage,072a37a9-b844-5474-847a-b75a6dfa454b,e8d2a50b-c332-5293-8552-b94b9d91eb41,96057038-9982-57a5-b50d-b4f8dd789948
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,DBTRG,cell_lines,Experimental Usage,e80d8e72-7c28-513f-a7e9-1f8e265ad8d1,e8d2a50b-c332-5293-8552-b94b9d91eb41,99a0ff7c-1a5f-5eb0-87da-fa7e21f9ceeb
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,T98G,cell_lines,Experimental Usage,0969c2f6-530b-571c-bd6d-830a622f88c1,e8d2a50b-c332-5293-8552-b94b9d91eb41,3549582f-ff39-5bfd-9c26-00e57d7805ae
PMID:32419643 | PMID:33934112 | PMID:25043298,10.1177/1533033820919759 | 10.1038/s41419-021-03716-6 | 10.1038/onc.2014.185,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Oncogenic role of Merlin/NF2 in glioblastoma.,,U251,cell_lines,Experimental Usage,60202787-d98a-5472-8735-265bed9bab56,2832d9c8-d1de-5d4a-a2f6-2f77085ff079,07eab8f2-f28c-5ea9-b326-a0c94aa93543
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,PNF-derived Schwann cells,cell_lines,Experimental Usage,83ec7f32-c989-53a1-a2a6-fa823c9767ee,fa90f484-3fc0-537f-bf88-12cc795487b4,9c2a04f2-e089-5e02-9ca9-9469e88a1762
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,GBM1 cell line,cell_lines,Experimental Usage,5b5ed71c-6989-519f-84cd-0849673510b6,191eeba4-4015-56fc-844e-366ad222e1fe,f7e2bb13-b9f5-5efc-a11e-4f2d3e0de0bb
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,JHH-0879 cell line,cell_lines,Experimental Usage,04d04711-606c-513d-838b-41ccfd31bf9e,191eeba4-4015-56fc-844e-366ad222e1fe,4ee95ac2-12db-5825-b4fc-fb2d8d0726ef
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S520,cell_lines,Experimental Usage,3d7e3707-fc00-58a5-9d9f-b5202863b554,be83907e-d10f-5ed4-8c63-f124c0cee202,622ddce9-3f48-5a21-8b4a-bbc4ea4219c2
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,88-3,cell_lines,Experimental Usage,7447bac6-552a-5835-84f2-08eb7f647c58,093853ec-9dd3-5b50-ba67-7a663ff9f31b,be58e700-bdd6-5072-9b52-fb4f88c3eb7d
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,YST1,cell_lines,Experimental Usage,95303fb7-f246-5999-b086-ca56efd81ff3,be83907e-d10f-5ed4-8c63-f124c0cee202,73fcc875-6ee3-59bb-8aa3-9fe75b50d858
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF98.4c,cell_lines,Development,2f430076-9a65-5379-84a3-f4f0ba88f0c0,9fede89a-8109-5177-b576-7ae5e61e4f17,69545a99-0d1d-50f0-87d9-9d4b28f1ab5c
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF00.10a,cell_lines,Development,1b4ccd99-c4ad-5ed0-b2fd-b912832dbf56,9fede89a-8109-5177-b576-7ae5e61e4f17,df25f9d1-b685-5fff-bc04-de2389b51c64
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF04.9a,cell_lines,Development,68e219ad-5abb-5a21-8605-af05c94d5a8f,9fede89a-8109-5177-b576-7ae5e61e4f17,bb399a47-3006-5d54-8754-c067e5a785a0
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i28cNF,cell_lines,Development,af3b5506-6126-5e83-b9bf-7798b570c6a5,9fede89a-8109-5177-b576-7ae5e61e4f17,4bc93c3e-3ee1-52da-b265-85b9b1858403
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i18cNF,cell_lines,Development,0c5f2a46-0efd-51c2-9b87-13a4909a06ee,9fede89a-8109-5177-b576-7ae5e61e4f17,b4d373d2-fec6-599c-a8e0-85102e5ab336
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i21cNF,cell_lines,Development,d5203a59-535e-5380-ab80-bfdffe4a75b3,9fede89a-8109-5177-b576-7ae5e61e4f17,47a890ce-e8e1-58e9-abd1-396f30119ee4
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,CCD-1112Sk,cell_lines,Experimental Usage,baa08bd2-365d-59db-86e1-f00e516cd399,182c9911-2c15-584f-98b9-7b0a2c64a536,b0020082-8199-5bf0-93fd-7d29f2da1365
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Rosetta2(DE3) competent cells,cell_lines,Experimental Usage,94757962-6ba2-59dd-9c6a-644d716e5e27,b4813465-f1a7-5d30-a546-abb518cc1dda,99356176-3cc2-5af4-a888-42ba353f379c
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,ST88-3,cell_lines,Experimental Usage,d5a6c08a-9a9f-5fab-8ce9-1dfa2c24b4c9,b3008494-8698-579f-be1c-ce4381b862e6,d101dfd6-6d34-512a-8c60-671a059abad3
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,T265p21,cell_lines,Experimental Usage,1b58e18f-1132-5bda-aabf-5ae5a3f13f6a,b3008494-8698-579f-be1c-ce4381b862e6,d6faa9df-da18-5590-9ecc-1f9eee8532f9
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,DS-red STS26T cell line,cell_lines,Experimental Usage,6710958e-20e5-5ec2-a1a2-007ab353f5e3,b3008494-8698-579f-be1c-ce4381b862e6,be4fc082-9500-5bc9-9d17-9aa1444b22a1
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,hTERT ipNF05.5,cell_lines,Experimental Usage,86ac0128-fc58-5086-9082-4647830836f8,f84f7c73-c19d-515b-93ad-9c99aae0cc9a,bc5b871f-4310-5cbd-b4d7-6bc40e5ae7dd
PMID:37140985 | PMID:38127282,10.1172/JCI168227 | 10.1158/1078-0432.CCR-23-2548,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT ipn02.3 2λ,cell_lines,Experimental Usage,0515ff95-b9ea-5a3f-b51c-302478fc4eb0,9fff242d-f4a8-5f8a-a3b9-a383109624d5,cfcf7036-c25c-587f-8308-4d95cf988d38
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,E13.5 DRG neurosphere cells,cell_lines,Experimental Usage,38a9b803-d789-51d6-b673-60025e5123cf,f84f7c73-c19d-515b-93ad-9c99aae0cc9a,8f78ce72-6d9c-590f-9091-ee42d875b5c5
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Daoy,cell_lines,Experimental Usage,9ac3e4e7-d7b6-5fb3-99c6-2d0fc70d9dec,17bcc00b-67b3-5fdb-be02-d523f712cdd2,7f63a873-2316-525c-8db0-67a071e3fa44
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,NF1-/- iPSC-derived neural crest cells,cell_lines,Experimental Usage,4bd19089-c984-5240-b95f-b750a31ef720,f3daad31-7203-5dc4-9d00-40eb7132df76,f31b01d0-5fd9-59a8-b044-3665fe3e9236
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT NF1 ipNF95.6 cell line,cell_lines,Experimental Usage,b80c2086-f0f8-57bb-9fd5-a3888829ce77,ac913aa3-1735-549f-bc14-f889b6fc4af2,9cac64e8-0ab3-50f0-a626-862876b9d5f8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF05.5-MX,cell_lines,Experimental Usage,4f05fee1-1910-5b82-bb68-f7b4b80a2cdd,6f7db849-02ea-5ec2-86d4-6d5a41aa5e88,23b8d261-4be1-5dec-a174-3bc7647bc94f
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.11b C/T,cell_lines,Experimental Usage,b7277fa0-d7dc-5a7e-b0c8-e57453be74ee,6f7db849-02ea-5ec2-86d4-6d5a41aa5e88,abd7894b-6f36-57e2-8cd7-c6ef1e190c68
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.3 2λ,cell_lines,Experimental Usage,2b94c339-158e-58f4-a4c1-748edb2107f5,6f7db849-02ea-5ec2-86d4-6d5a41aa5e88,e4c7659a-3505-5413-aca5-395f2a0c10f8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.8,cell_lines,Experimental Usage,6f45998e-a3a7-5a60-bb52-c38a4b30b2a5,6f7db849-02ea-5ec2-86d4-6d5a41aa5e88,3565927d-e858-5eac-aeea-3b0bfad42bdf
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.11b,cell_lines,Experimental Usage,2d3657c0-c193-52ae-ab2a-25273f940154,e4c90cba-6892-5708-aa15-ef0b87142fe0,4759e8ba-b29a-58eb-bad8-160f243e4f6e
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.6,cell_lines,Experimental Usage,1200b509-be23-5290-b09c-6901566b8727,e4c90cba-6892-5708-aa15-ef0b87142fe0,6c3cc53f-b3e5-58dc-bbe2-f0a8d11e9a76
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF94.3,cell_lines,Experimental Usage,e172c4b8-f6e9-58e0-b1a5-b4a61faa4f0d,e4c90cba-6892-5708-aa15-ef0b87142fe0,cda1c13a-47d6-5e8a-933f-805a61108d62
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW18.2,cell_lines,Experimental Usage,8efeac4d-ac2b-5412-8dcc-e5ff7664c788,e4c90cba-6892-5708-aa15-ef0b87142fe0,cf536d94-52ae-5b02-b0af-27ea0bcd85aa
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW23.3,cell_lines,Experimental Usage,0826bf05-bea4-55ea-9956-c2431aeddb8e,e4c90cba-6892-5708-aa15-ef0b87142fe0,bdaa0134-6ccc-58a1-96fe-06048cca5f31
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,KT21-MG1,cell_lines,Experimental Usage,83e001a9-f5b5-57a1-ac4a-3047e2acbd16,865f5011-5b7e-5810-85d5-63c582ea12bf,e0c247ed-04f8-5270-bb80-c82f5b38bcaf
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,293FT,cell_lines,Experimental Usage,b89c7020-3257-514c-bcbf-ae15c45e314c,865f5011-5b7e-5810-85d5-63c582ea12bf,460c872a-9d2f-5138-96ec-d90b4c3c07d5
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,NF2 primary fibroblasts,cell_lines,Experimental Usage,4a45fdd1-9475-5593-ba58-d988ee9236ed,6af169cf-6643-50d1-af2e-726b5b582bca,3b885fc6-2b81-5135-b19d-41858172ab16
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Primary human vestibular schwannoma (VS) cell cultures,cell_lines,Experimental Usage,907dc753-7d04-582e-8540-7ee8acf51c42,95f1082d-f96e-5e7d-8f17-7f4a01bed966,fa2d697c-87d5-5ca6-8521-55dfc7fcb50f
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,Primary normal rat Schwann cells,cell_lines,Experimental Usage,2e53b7b7-5929-5882-a588-ae185fbbd891,f8b03487-e857-596e-98f5-344819871865,59af1a48-5ee8-5532-90c0-5083623295ab
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 Mixed Clones,cell_lines,Experimental Usage,95e6d4d5-e824-52e5-b61e-bb67be87be12,534364ec-5bd4-5066-8aab-1b44350472e7,288557ae-3aa6-5fe4-b4f2-c31f47d02d5c
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Nf1flox/flox bone marrow stromal cells,cell_lines,Experimental Usage,4e69a044-d3ea-5e74-8e2f-0408bea1bced,98f04c40-6c31-53bf-a60f-ca873e104087,2cfe2fe7-e0f5-5eec-8a23-6ca6e83eb7ad
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,DH5α bacteria,cell_lines,Experimental Usage,74ed9bb8-7699-5833-9337-cbacd968dbf1,5ff33f31-22ea-51f6-80a7-083a5a4086d0,7480155a-57b0-57dc-922d-abf33faa35e1
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,tail-tip fibroblasts (TTFs),cell_lines,Experimental Usage,cf34bad6-4fb2-534b-b278-c7f539efd9d1,0a012be1-237b-5d4e-827b-677e1675a59c,ac5786d9-0742-5caf-a7fc-62296288ec15
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Neural stem cells,cell_lines,Experimental Usage,d305db74-c751-5bdd-af63-c2e3ee895391,b2eac4d3-8154-523b-b09a-6ef969dbe85f,e4274a5c-5e95-5610-aeb8-5fa130b1f8c4
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2-deficient spinal cord neural progenitor cells,cell_lines,Experimental Usage,dea21cf1-7664-5397-a53e-e20915585dfc,54cd37ba-40ed-5391-99a0-0c3e536cb934,ef45ea0c-0c92-5916-b2bb-3e9c6f13c3ac
PMID:41001593 | PMID:32948135,10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,NSF1,cell_lines,Experimental Usage,7b6c33ae-80c6-58fb-9b72-7af33ce751cb,a6120f0c-6961-5b3e-be52-3a366d491fad,a294f2eb-af7f-5ab4-887a-5bc0b414a9bb
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,BRGN,cell_lines,Experimental Usage,476b694e-5c7b-5eff-ba88-4873d85e893f,d40edf1b-e3a9-5d8d-be4f-1143945ba052,34ebc8df-ab6a-570c-9a4d-1715a7c7f0e1
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,primary human Schwann cells (HSC),cell_lines,Experimental Usage,46392633-e489-5bf1-9c84-f13f75b5b027,d40edf1b-e3a9-5d8d-be4f-1143945ba052,c60fdd8e-c993-5ad6-874b-29c519f3858c
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Normal human Schwann cells (HSC),cell_lines,Experimental Usage,9b132f11-ff5c-508c-a577-d04a2df846ec,d9a7289e-feee-568c-9764-232590a16e2d,3254ce41-7862-57ab-935c-4b6f282d4738
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,B8 fibroblasts,cell_lines,Experimental Usage,cb4dfcf1-22c7-5d58-9f91-76ac12a7abba,f32dd9db-df78-56f6-9e6f-c9fed4cfff2c,7f3d32b3-ede5-5eb8-9a19-d166f7b27814
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,95.6,cell_lines,Experimental Usage,58b337b0-b7a4-5cc8-828d-a40f76225507,530910bf-7a1c-50fa-8d7c-5ddf953165bb,995f5d9c-d3eb-5dbf-822d-dd2a4bca5a8b
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ipn02.3,cell_lines,Experimental Usage,517811ae-597e-53f9-82c0-c9e3d3a31531,530910bf-7a1c-50fa-8d7c-5ddf953165bb,f3d45911-0f4c-54fa-a862-1433f7460f1f
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–009,cell_lines,Experimental Usage,333a3c2f-3e3c-5656-ac35-860dbb11ead8,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,194c9a0e-18ca-5ebb-9e5e-93a962a93163
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–055,cell_lines,Experimental Usage,da1de80d-463e-5fc4-b4c9-d322f7086f3e,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,e0625198-9dc5-521c-82ef-a61e1158c796
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–060,cell_lines,Experimental Usage,d40716cd-3de0-5fb3-a659-5e4079591827,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,d420daba-7fa5-5556-aa66-a9d02c26af82
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–074,cell_lines,Experimental Usage,4a6aab13-7a5a-5a96-9907-fa031368c064,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,220fb2ec-c4d5-52d8-9fc6-8059b1ac6f56
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–077,cell_lines,Experimental Usage,9df8d25f-ce00-5bd1-8782-8b81046d4c13,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,c1327f0c-441a-5f3c-a9e3-5ef76df56153
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,cNF-Skindex,clinical_assessment_tools,Experimental Usage,6f874e06-8267-50be-9c59-ad272942e2fb,0fe7de6e-65a8-5a2b-bec9-f97f0c9dfc00,41690aa7-93cc-5c85-8579-9367d647b0b1
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tools,Development,0734b073-bc3d-5f6a-94f4-84fe23b17be1,ccf34650-cde9-5b19-9c9d-2f0496c47156,8d085b33-a06f-5476-957f-c1d438011c8c
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cirrus HD-OCT,clinical_assessment_tools,Experimental Usage,aa40c7ee-678c-5a51-9096-a63a4d351f0a,07838565-b674-53d8-9b2d-c0021a95159e,57f38f1c-aef0-5b8b-a0d6-1150edeeab07
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Teller acuity cards,clinical_assessment_tools,Experimental Usage,91d39f8a-a23c-5280-bcb7-09d690acc07b,07838565-b674-53d8-9b2d-c0021a95159e,36ba0734-10fe-5733-b761-fed8ba10b043
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cardiff acuity cards,clinical_assessment_tools,Experimental Usage,a9cb8415-66d5-56e7-9a29-2598d0f3eda6,07838565-b674-53d8-9b2d-c0021a95159e,e4d24f91-9ec0-5c15-bccb-11594e0f2602
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Lea cards,clinical_assessment_tools,Experimental Usage,477a6edc-6167-58d6-8bf2-c8229749d3ff,07838565-b674-53d8-9b2d-c0021a95159e,71b9e485-eb19-5321-b8b5-cccda706fe04
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,KM (Konstantin Moutakis) cards,clinical_assessment_tools,Experimental Usage,9d5cd7f2-a777-5af9-9cd2-41343bafc662,07838565-b674-53d8-9b2d-c0021a95159e,dd140fcf-1389-5b90-94da-8978ca70bf86
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Humphrey Field Analyzer perimetry,clinical_assessment_tools,Experimental Usage,21b921b7-0a81-55dc-b026-047ab41d36b7,07838565-b674-53d8-9b2d-c0021a95159e,cbb461af-25d6-591f-864c-b4808d7d6989
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,World Health Organization Categories of Childhood VI scale,clinical_assessment_tools,Experimental Usage,132af402-7f25-5c61-8388-9590983e2bfa,07838565-b674-53d8-9b2d-c0021a95159e,814144de-175f-512e-9299-125ece9cc7e4
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,Likert scale questionnaire,clinical_assessment_tools,Experimental Usage,4f1dd2b3-e65d-5989-ba2e-4660a5b4cd55,6830a023-9b5c-5a09-95de-fc3861b093aa,5b689dd7-5fc9-567b-9415-ba38fc1d245c
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,BoN (Burden of NF1) questionnaire,clinical_assessment_tools,Development,17d28945-5619-5d56-ba79-00f5a2bb28c4,ff4c2d09-73b0-525c-9478-e3e1c6e9682c,bd963f64-921c-550d-9232-3c624b167c15
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,Dermatology Life Quality Index (DLQI),clinical_assessment_tools,Experimental Usage,7f9eae4d-057a-5b31-82fe-1b6481c14d67,ff4c2d09-73b0-525c-9478-e3e1c6e9682c,d3b1dfbf-71ee-5e64-aa45-833969852d65
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,SF12,clinical_assessment_tools,Experimental Usage,592b9f03-bdf9-50af-b596-8a13b4b555e6,ff4c2d09-73b0-525c-9478-e3e1c6e9682c,cd5ce5c7-6228-5faf-9949-4ca03c7e99c1
PMID:33085177 | PMID:38499890,10.1002/mgg3.1530 | 10.1186/s41687-024-00714-y,"The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas. | The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,PlexiQoL,clinical_assessment_tools,Development,0382a519-47f2-5674-bdef-43f7d7870a59,cede9ef0-255b-5f47-b1e2-9cd325889963,1b6e2a2a-af7b-595c-ac77-fca8a5b13e5d
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,DINs (Deep Interactive Networks),computational_tools,Development,427022ea-30bf-55d4-9536-c1c038d29817,c857d81e-5c94-5f0b-a9d3-8b814b08d3f1,4a49f884-8997-5884-939d-d32a027ba173
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,RENOVO-NF1,computational_tools,Development,ac513c73-c841-57fb-a231-83630df75bf7,7ae7d9c2-a4ec-5110-8624-4867400dace2,f6f44b1b-1184-59e7-83fd-bc9eade2284f
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,shNF1,genetic_reagents,Experimental Usage,06db1f73-d104-5fd8-bd3d-8a2352bed9d2,686ba2dd-21f7-5c0f-9c35-4a10134fe88f,31f7668c-a012-593c-8da4-f3cd33132a7f
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,NF1 gRNA,genetic_reagents,Experimental Usage,b13b1850-2e06-5e2d-8a22-4cd6f9a47d33,abb89502-7575-51d1-9884-ddca97a2d316,bca1003e-cc07-5aef-bafa-63c5c19414f9
PMID:31836666 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1 isoform 2,genetic_reagents,Experimental Usage,bb2df413-72b9-5f11-a72a-c84e6095f6a8,cfff6c07-6540-5a03-8a19-d1158560cd09,06cfd3ee-3729-5709-b480-369992a65417
PMID:33273014 | PMID:29715273 | PMID:30274821 | PMID:26219339 | PMID:24595234,10.1074/jbc.RA120.014960 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0090853,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,NF2,genetic_reagents,Experimental Usage,0f2a9f25-f256-5a9d-8311-a86ee1f2cf75,d5f3621f-a9b1-592c-b06f-cf4df05097a9,c732c818-394c-51d3-99d5-c960a3514166
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,SPRED1,genetic_reagents,Experimental Usage,f7dcbd69-232f-50a4-ba9d-822be53b90cc,e687328f-6e1a-58b4-bed5-5f4a0380626e,c97c2874-6530-5a9f-be63-3228031d0f39
PMID:32461556 | PMID:38481529 | PMID:39890807 | PMID:34646065 | PMID:37446790 | PMID:34011935 | PMID:29670214 | PMID:37140985 | PMID:36241865,10.1038/s41467-020-16432-0 | 10.3389/fcell.2024.1359561 | 10.1038/s41598-024-84493-y | 10.1155/2021/9386823 | 10.3390/molecules28135128 | 10.1038/s41419-021-03802-9 | 10.1038/s41598-018-24310-5 | 10.1172/JCI168227 | 10.1038/s12276-022-00850-9,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Survival and | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Restoring functional neurofibromin by protein transduction. | Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Nf1,genetic_reagents,Experimental Usage,3116577c-3599-505d-a90a-e04b5d80c3a9,23c57071-b75b-5d71-a8c5-4f57f690ac5b,182aad93-5fa7-51dc-b298-2c359c28371f
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,Merlin,genetic_reagents,Experimental Usage,321f4779-13ca-5a1a-be45-b299759fcaf5,a64e9b65-068b-5d68-8369-dcfe8e1f7a64,83ecd84b-4ddc-52b4-9b65-26baf7f4e30d
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNf1,genetic_reagents,Experimental Usage,597c6712-d495-58e1-8004-3fede96f345d,0d572b03-b1ed-5e1d-9f5a-0a036c3924ff,6a54cddc-272f-5cfc-b063-48f9969606ab
PMID:24509877 | PMID:35393510 | PMID:16835260 | PMID:38000020,10.1038/onc.2013.506 | 10.1038/s41418-022-00991-4 | 10.1093/hmg/ddl165 | 10.1126/sciadv.adg8876,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,NF1-GRD,genetic_reagents,Experimental Usage,75bedd3d-de9f-50fb-b02a-5f858bdf5d95,009a9b67-d199-5bcf-8f59-3ab78c271baa,e38aa0ec-2c20-56e8-a848-a9dc9af01121
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1-targeting TALEN,genetic_reagents,Experimental Usage,636d40b2-4d48-51f1-b36a-16070f50fd9a,d2f07474-f43f-50f7-abc1-ecf76627be65,47c4dd20-2b55-5df4-8b68-67057a9b3504
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 DLR,genetic_reagents,Experimental Usage,cdb8a219-076a-5c66-a879-c86f6eadaeeb,d2f07474-f43f-50f7-abc1-ecf76627be65,01acf277-b66a-501f-9790-86b8b22e9a4a
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 flox,genetic_reagents,Experimental Usage,265957c5-7e6e-5869-b338-790b008be252,9c33f2c2-8d6b-5387-a09b-d1eaf1d44dd0,fce11210-d4af-59a8-9332-478ee203fab0
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 KO,genetic_reagents,Experimental Usage,ac329603-1408-52ab-8a3e-ef8ced57fd09,9c33f2c2-8d6b-5387-a09b-d1eaf1d44dd0,9eac762d-fe39-5dd6-92f3-8ef4b951e1c2
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,human neurofibromin,genetic_reagents,Experimental Usage,b7085b43-00fc-527a-b0b3-9bd3e2466be9,91102d9b-3d20-56e0-90c2-ca7bd11b41fc,2af24a58-4a08-5f34-b39a-00372f6d22a8
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,NF1 capture probes,genetic_reagents,Experimental Usage,4f1d7d73-108d-5a2e-8c55-60630dd37213,81eaad47-a8e9-576a-a11f-78bfca11d133,6aef8f45-05fd-54b2-a19a-73f1688f586e
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,neurofibromin 2,genetic_reagents,Experimental Usage,cb446af9-29b9-5291-90f6-d922ccad4702,2f4c6836-84ea-5091-b651-3c23a073ed61,a7926f94-fdf4-5cc2-8b55-e3a892f2de94
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,NF2 shRNA,genetic_reagents,Experimental Usage,e7b21490-1fd4-5a4f-af08-b98df0fa7f4c,abf6a2b1-3b0c-5df8-a16e-d264bd0469bc,cb62b06d-517e-5577-b058-c6dc50f63e15
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,Spred1(EVH1),genetic_reagents,Experimental Usage,9a69fa4c-c95d-5eb7-8ac2-d80d475b3d26,0cdefd2a-bf11-5ffc-a43b-0f263626c7a8,9762d0c4-3a1e-5b5f-bcb2-68b7de13fc26
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,NF2 TET,genetic_reagents,Experimental Usage,18f7176d-5d4d-5081-9541-48d3ffc613c7,f902443e-333e-54eb-83a6-e463afe3e86f,31ce5396-5fef-5952-973a-b36931af7123
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin isoform 1,genetic_reagents,Experimental Usage,7327acb0-3da8-5996-a8c3-33a4266d20ee,b4813465-f1a7-5d30-a546-abb518cc1dda,58f25ef1-d11b-59e3-9649-436ff28ce3e7
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin(S518D) and Merlin(S518E) mutants,genetic_reagents,Experimental Usage,b6437392-e761-55f3-a2d7-53e083f3b2f0,b4813465-f1a7-5d30-a546-abb518cc1dda,35b70a2e-944e-5366-90e3-312dccf7dd9b
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Merlin siRNA,genetic_reagents,Experimental Usage,95008ac5-da45-58b7-af96-08e5a18fa4b5,107350fd-06aa-5a46-b6d8-3bc0f5fccb45,cbc093da-7e68-5b32-818b-f5c9fa24b551
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,HA-Merlin,genetic_reagents,Experimental Usage,a255703a-bca5-5e3e-81c3-2868bd068c72,107350fd-06aa-5a46-b6d8-3bc0f5fccb45,e27b27fb-155e-5921-902e-5e9db24a264a
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518A HA-Merlin,genetic_reagents,Experimental Usage,6d297b9b-4625-5027-bd4e-e11fd87525cf,107350fd-06aa-5a46-b6d8-3bc0f5fccb45,f650c0fa-4167-5038-a70d-c72ac33d2495
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,nf2a/b-4sgRNA,genetic_reagents,Experimental Usage,bf0b28b1-d426-5d34-9730-18c2071952dc,4ae7a300-d8f1-5cab-815b-f1652288fa55,6f302b53-8c6e-5217-b02e-577bc50d14fe
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,1276P NF1 GRD,genetic_reagents,Experimental Usage,34f0456d-3c38-5053-af1f-24c0c8de1e7c,895f5042-5945-585d-b4a3-3d496cafdbf3,7efb0f81-781b-508c-8b51-bd1bc42050d0
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Cas9 and sgRNAs targeting Nf1+Cdkn2a,genetic_reagents,Experimental Usage,b59cc241-98af-5ff2-b8fd-0ce739680f63,8d5a7ccc-1277-5b40-9917-7d1f726379ab,3e26c266-237c-50ce-bf42-389a5d88cff1
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-002,patient_derived_models,Experimental Usage,9deea661-99fd-5137-828f-2d2b4b5706e9,6764b278-d54d-52a4-82e4-db8f073ca068,a238b29c-bfe1-5abe-9f2e-f019bf145305
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-031,patient_derived_models,Experimental Usage,3d0a3b88-eb7f-5fbb-abf1-3ab5395da5c0,6764b278-d54d-52a4-82e4-db8f073ca068,df878292-d243-5bc5-8fe0-1c11a30decb5
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c PDX,patient_derived_models,Experimental Usage,732b9684-0f30-5c2c-9ad0-ce0789bb4f94,f9a62cfb-88fc-55b1-a269-f3fe2b0da09f,0ad52ce6-3d08-5eae-afa7-4070c3f917b1
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-225 PDX,patient_derived_models,Experimental Usage,87b9f446-ce8e-581b-86c0-c0c145c0fb38,f9a62cfb-88fc-55b1-a269-f3fe2b0da09f,8f471752-d637-59f2-9b80-30d1566f673a
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-386 PDX,patient_derived_models,Experimental Usage,7b7a19b6-d06e-503a-b33a-bfc3695c1d21,f9a62cfb-88fc-55b1-a269-f3fe2b0da09f,18cdb28b-9cef-51f5-b411-2b0939e0724d
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-545 PDX,patient_derived_models,Experimental Usage,76d410b8-44cc-5c60-b3c3-3f29d1008446,f9a62cfb-88fc-55b1-a269-f3fe2b0da09f,457d0b4b-25ae-5a5d-8dfc-f9cc116069aa
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-2 PDX,patient_derived_models,Experimental Usage,cde5fdb9-e724-5e97-b2ae-d7387f77a658,f9a62cfb-88fc-55b1-a269-f3fe2b0da09f,eb1ec3b8-3373-56da-811c-35ba7f43da05
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-3-002 PDX,patient_derived_models,Experimental Usage,99abaeda-7875-51c6-95df-b765fe36d7da,f9a62cfb-88fc-55b1-a269-f3fe2b0da09f,64903d54-1f35-5c00-90d5-9dae1f854021
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Patient-derived xenograft (PDX) MPNST model,patient_derived_models,Experimental Usage,0258f036-e724-574e-bae6-c114aea19fb3,c079a8f5-6f86-5f1e-8b61-d414dade9904,98820301-8821-5496-8914-0f29af4bac44
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01 PDOX,patient_derived_models,Experimental Usage,3631dd82-cdff-53ea-a9db-c1a5ea2c96e1,294191e1-49c3-569a-8ac9-0d1eff798717,878e2a16-a7c0-52f0-aae3-604a82662542
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-09 PDOX,patient_derived_models,Experimental Usage,fdc20dd1-5d8c-555a-8a15-5c5d5494855b,294191e1-49c3-569a-8ac9-0d1eff798717,1a1e5f49-9944-5fdc-a2bc-507f5a611d38
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,vestibular schwannoma xenografts,patient_derived_models,Experimental Usage,f68c3c8b-a765-5699-87a1-756644c86325,58455c88-bf11-5b9d-9b3f-e368a533844b,05082e19-1068-552d-b41a-8de52c52fc44
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Cutaneous neurofibroma samples,patient_derived_models,Experimental Usage,f5fe1942-3042-5f52-946e-b5ae38b85b37,c85145d2-03f6-5ed2-971c-370356cf4a08,22f0b8cc-5350-5fc3-82cc-8d0db0767a1b
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,human neurofibroma xenografts,patient_derived_models,Experimental Usage,ec6229d2-9722-52a2-b9fe-a054e5a1ec5b,2acfeda4-d927-5608-a4d7-7bace257673c,e3eae52e-f08c-50ac-a9cf-1cf261cce77e
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,RHT-92,patient_derived_models,Experimental Usage,8284ac89-a782-5b64-a60e-a06ba93242a2,530910bf-7a1c-50fa-8d7c-5ddf953165bb,6a3d4fbb-c8ee-5d95-8b3d-f0b5b3991295
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,NF90.8,patient_derived_models,Experimental Usage,b0ce932e-7d01-55b9-8372-6443e96b4faa,aa79d0a8-45d4-5bdc-af48-1b8a3a34eb9d,14e76c31-31f8-5251-91e2-27ee74b3d931
